Introducing the new BTS guideline:The investigation and management of pleural malignant mesothelioma by Woolhouse, Ian & Maskell, Nick A.
                          Woolhouse, I., & Maskell, N. A. (2018). Introducing the new BTS guideline:
The investigation and management of pleural malignant mesothelioma.
Thorax, 73(3), 210-212. https://doi.org/10.1136/thoraxjnl-2017-211416
Peer reviewed version
License (if available):
CC BY-NC
Link to published version (if available):
10.1136/thoraxjnl-2017-211416
Link to publication record in Explore Bristol Research
PDF-document
This is the accepted author manuscript (AAM). The final published version (version of record) is available online
via BMJ at http://dx.doi.org/10.1136/thoraxjnl-2017-211416 . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
 1 
Post SOCC draft 29/08/2017 
 1 
 2 
BTS Guideline for the investigation and management of malignant pleural 3 
mesothelioma 4 
 5 
On behalf of the BTS Mesothelioma Guideline Development Group 6 
 7 
Post public consultation draft 8 
For final approval by BTS Standards of Care Committee (SOCC) 9 
 10 
 11 
Block yellow shows GDG response to public consultation 12 
Light blue show GDG response to SOCC comments in June 13 
 14 
 15 
 16 
 17 
 18 
Contact:  19 
British Thoracic Society, 17 Doughty St, London WC1N 2PL 20 
sally.welham@brit-thoracic.org.uk 21 
louise.preston@brit-thoracic.org.uk   22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 2 
Post SOCC draft 29/08/2017 
Contents 30 
 31 
Executive Summary 32 
 33 
Summary of recommendations 34 
Glossary and abbreviations 35 
Tables / charts /algorithms 36 
 37 
Section 1  Introduction 38 
1.1 Aim of the Guideline  39 
1.2 Intended users of the guideline and target patient populations 40 
1.3 Areas covered by the guideline 41 
1.4 Areas not covered by the guideline 42 
  1.5 Limitations of the guideline 43 
 1.6 Members of the guideline development group 44 
 1.7 Representation 45 
 46 
Section 2 Methodology of Guideline production 47 
 2.1 Establishment of guideline development group 48 
 2.2 Methodology 49 
2.3 Summary of key questions and literature search 50 
 2.4 Methodology and appraisal of the evidence 51 
 2.5 Planned review and updating of the guideline  52 
 2.6 Declarations of interest 53 
 2.7 Stakeholders 54 
 55 
Table 2.1 SIGN levels of evidence 56 
Table 2.2 SIGN grades of recommendation 57 
 58 
Section 3 Clinical features which predict the presence of mesothelioma 59 
Section 4 Obtaining a histological diagnosis 60 
Section 4 Staging systems 61 
Section 5 Imaging modalities for diagnosing and staging 62 
 5.1 Diagnostic imaging 63 
 5.2 Evidence on staging 64 
 5.3 Technical factors influencing diagnosis and staging 65 
 5.4 Clinical impact 66 
 67 
Section 6 Pathological diagnosis 68 
 6.1 Diagnosis and sub-typing 69 
 3 
Post SOCC draft 29/08/2017 
 6.2 Individual IHC immunohistochemistry data 70 
 6.3 Diagnosis in cytology 71 
 72 
Section 7 Use of biomarkers 73 
 74 
Section 8 Factors determining prognosis and timing of treatment 75 
 76 
Section 9 Fluid management 77 
 78 
Section 10 The role of surgery 79 
 80 
Section 11 Systemic anti-cancer treatment 81 
 11.1 First line 82 
 11.2 Second line 83 
 84 
Section 12 Radiotherapy 85 
 12.1 Port / drain site 86 
 12.2 Mmulti-modality treatment 87 
 12.3 Ppalliation 88 
 89 
Section 13 Symptom control 90 
 91 
Section 14 Care and management 92 
 14.1 Care in multi-disciplinary teams 93 
 14.2 Information needs of patients 94 
 14.3 Follow-up strategies 95 
 96 
 97 
 98 
 99 
Disclaimer: 100 
 101 
Healthcare providers need to use clinical judgement, knowledge and expertise when deciding 102 
whether it is appropriate to apply recommendations for the management of patients. The 103 
recommendations cited here are a guide and may not be appropriate for use in all situations. The 104 
guidance provided does not override the responsibility of healthcare professionals to make decisions 105 
appropriate to the circumstances of each patient, in consultation with the patient and/or their 106 
guardian or carer.  107 
  108 
 4 
Post SOCC draft 29/08/2017 
Glossary and abbreviations 109 
ADC  Apparent diffusion coefficient 110 
AJCC  American Joint Committee on Cancer 111 
ASC  Active symptom control 112 
AUC  Area under the curve 113 
CI  Confidence interval 114 
CT  Computed tomography 115 
CRP  C-reactive protein level 116 
DWI-MRI Diffusion-weighted magnetic resonance imaging 117 
EORTC  European Organisation for the Treatment of Cancer 118 
EPD  Extended pleurectomy decortication 119 
EPP  Extra-pleural pneumonectomy 120 
GDG  Guideline Development Group 121 
GPP  Good practice point 122 
HA  Hyaluronic acid 123 
HR  Hazard ratio 124 
IASLC  International Association for the Study of Lung Cancer 125 
IHC  Immunohistochemistry 126 
IPC  Indwelling pleural catheter 127 
IQR  Interquartile range 128 
LDH  Lactate dehydrogenase 129 
MDTs  Multi-disciplinary teams 130 
MPF  Megakaryocyte potentiating factor 131 
MPM  Malignant pleural mesothelioma 132 
MRI  Magnetic resonance imaging 133 
NCAT  National Cancer Action Team 134 
NICE  National Institute for Health and Care Excellence 135 
NLR  Neutrophil-to-lymphocyte ratio 136 
OPN  Osteopontin 137 
OS  Overall survival 138 
PET  Positron emission tomography 139 
PET-CT  Positron emission tomography-computed tomography 140 
PICOT  Patient, Intervention, Comparison, Outcome and Time 141 
PLR  Platelet-to-lymphocyte ratio 142 
PP  Partial pleurectomy 143 
PS  Performance status 144 
PTM  Procedure-tract metastases 145 
RCT  Randomised controlled trial 146 
RT  Radiotherapy 147 
SMRP  Soluble mesothelin related peptides 148 
SOCC  Standards of Care Committee (British Thoracic Society) 149 
SUV  Standardised uptake values  150 
UICC  Union for International Cancer Control 151 
US  Ultrasound 152 
VAT  Video assisted thoracoscopy 153 
WBC  Total white blood count 154 
 155 
 156 
 157 
 5 
Post SOCC draft 29/08/2017 
SECTION 1: INTRODUCTION 158 
1.1 Aim of the Guideline 159 
The key aim of this Guideline is to provide detailed, evidence-based guidance for the investigation of 160 
suspected malignant pleural mesothelioma (MPM) and the subsequent care and management of 161 
individuals with proven MPM.  MPM is a rare cancer where the malignancy affects the pleura, a thin 162 
membrane of lubricating cells that lines the lungs and chest wall. The focus of this guideline is MPM 163 
as it is far more common than mesothelioma occurring in the abdomen.  There is approximately 1 164 
case of peritoneal mesothelioma to every 12 cases of MPM (http://www.mesothelioma.uk.com/). 165 
The 2016 Mesothelioma Audit data reported that in the UK in 2014 pleural mesothelioma accounted 166 
for 2179 cases (97%), with 70 peritoneal cases (approx. 3%) [1]. 167 
In 2007 the BTS statement on mesothelioma was published in response to a request from the 168 
National Health Executive in England [2].  The BTS has reviewed this statement and is of the opinion 169 
that the publication is no longer fit for purpose as an up to date reference guide for health care 170 
professionals.    The 2007 statement did not attempt to provide a comprehensive review of all 171 
relevant published literature and since the publication of the statement the BTS has achieved NICE 172 
accreditation for its guideline production process.  The Standards of Care Committee of the British 173 
Thoracic Society established a guideline development working group, chaired by Professor Nick 174 
Maskell and Dr Ian Woolhouse in 2014.   175 
The main cause of mesothelioma is breathing in asbestos dust – approximately 85% of all male 176 
mesotheliomas are attributable to occupational asbestos exposures.  The use of products containing 177 
asbestos was banned in the UK in 1999.  The latency period between first exposure and 178 
development of the disease is very long, typically 30-40 years.   179 
Cases of mesothelioma were recorded systematically from the late 1960s. The incidence of 180 
mesothelioma has been increasing steadily since then, and current predictions suggest there will 181 
continue to be approximately 2,500 deaths per year for the rest of this decade, before numbers 182 
begin to fall. (HSE http://www.hse.gov.uk/Statistics/causdis/mesothelioma/mesothelioma.pdf).  183 
The largest dataset of MPM in the UK comes from the National Lung Cancer Audit report which 184 
described 8740 cases seen in hospitals in England and Wales between 2008 and 2012 [3]. Eighty 185 
three percent of patients were male and the median age at diagnosis was 73 years.  Sixty seven per 186 
cent of patients received active anti-cancer treatment (chemotherapy, radiotherapy and surgery) 187 
and overall median survival was 9.5 months, with one year and three year survival rates of 41% and 188 
12%, respectively. The report identified significant variation in treatment and outcomes across the 189 
UK which further highlights this need for an evidence-based guideline to facilitate the highest 190 
standards of care for all mesothelioma patients in the UK. 191 
 192 
1.2 Intended users of the guideline and target patient populations 193 
The Guideline will be primarily of interest to healthcare professionals working within the NHS, but 194 
the aim was to make the Guideline as applicable to international practice as possible so that it may 195 
be used across Europe and America as appropriate.  Given the nature of MPM, the majority of the 196 
guideline will be relevant to secondary care-based specialists; however symptom recognition, 197 
management and follow up are all relevant to community based specialities. 198 
Intended users: 199 
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• Primary care – GPs and practice nurses 200 
• Hospital specialist teams in respiratory medicine, oncology, thoracic surgery and palliative 201 
care. 202 
• Hospices / community teams 203 
• Specialist nurses (including lung cancer and palliative care) 204 
• Radiologists 205 
• Pathologists 206 
 207 
 208 
1.3 Areas covered by the guideline 209 
Inclusion  210 
- The epidemiology and incidence of mesothelioma in the UK and worldwide 211 
- The preferred investigation pathway of suspected cases of MPM 212 
- Consider special situations including:  213 
- Imaging 214 
- Histology /Cytology  215 
- Frail patient not fit for invasive tests 216 
- Biomarkers 217 
- Role of Mesothelioma MDTs 218 
- Outline best practice in oncological management: 219 
- Role of chemotherapy 220 
- Place for radiotherapy 221 
- Role of surgery 222 
- Guidance on palliation in MPM 223 
- Guidance on providing patients with relevant disease specific information, including 224 
medicolegal/compensation issues 225 
- Summary of future therapeutic agents that might be available within next 5 years 226 
- Summary of major MPM recommendations 227 
 228 
 229 
1.4 Areas not covered by the guideline 230 
Non pleural mesothelioma is excluded from this Guideline. 231 
 232 
1.5 Limitations of the guideline 233 
Healthcare providers need to use clinical judgement, knowledge and expertise when deciding 234 
whether it is appropriate to apply recommendations for the management of patients. The 235 
recommendations cited here are a guide and may not be appropriate for use in all situations. The 236 
guidance provided does not override the responsibility of healthcare professionals to make decisions 237 
appropriate to the circumstances of each patient, in consultation with the patient and/or their 238 
guardian or carer.  239 
 240 
 241 
 242 
1.6 Members of the guideline development group  243 
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The GDG was chaired by two respiratory consultants – Dr Ian Woolhouse and Professor Nick Maskell.  244 
The GDG had a wide membership with representation from respiratory medicine, thoracic surgery, 245 
medical oncology, radiotherapy, pathology and primary care.  A patient representative was on the 246 
group for the duration of the process.  Those on the group were not required to be BTS members.  A 247 
full list of members can be seen at Appendix 1. 248 
1.7 Representation 249 
Professor Dean Fennell and Dr Jeremy Steel represented the Association of Cancer Physicians.  Dr 250 
Anthony Edey represented the British Society of Thoracic Imaging. Professor Corinne Faivre-Finn 251 
represented the British Thoracic Oncology Group. Professor Keith Kerr represented the Royal College 252 
of Pathologists.  Dr Ian Woolhouse represented the Royal College of Physicians.  Mr John Edwards 253 
and Mr Apostolos Nakas represented the Society of Cardiothoracic Surgeons.  Dr Corinne-Faivre-Finn 254 
and Dr Anthony Edey represented the Royal College of Radiologists.  Dr Tim Peel represented the 255 
Association for Palliative Medicine.  Dr Steve Holmes represented the Primary Care Respiratory 256 
Society UK.  Ms Liz Darlison represented the Royal College of Nursing (RCN).  Dr Graham Abbott, Mr 257 
Paul Astle and Mr John Gillies were the patient representatives on the group. 258 
 259 
SECTION 2: METHODOLOGY OF GUIDELINE PRODUCTION 260 
2.1 Establishment of guideline development group 261 
The Guideline Development Group (GDG) was convened in June 2014, with the first meeting taking 262 
place in October 2014.  The full GDG met six times during the development of the guideline and kept 263 
in close contact by teleconference and email throughout the process. 264 
2.2 Methodology 265 
This guideline is based on the best available evidence and follows the NICE accredited BTS guideline 266 
production process. The methodology used to write the guideline adheres strictly to the criteria as 267 
set by the AGREE II collaboration, which is available online www.agreetrust.org/resource-268 
centre/agree-ii/ . The British Thoracic Society Standards of Care Committee guideline production 269 
manual is available at: https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/ 270 
2.3 Summary of key questions and literature search 271 
Clinical questions were gathered in the PICOT (Patient, Intervention, Comparison, Outcome and 272 
Time) format.  The key questions are summarised below. 273 
• Which clinical features predict the presence of MPM? 274 
• In patients with suspected MPM (post CXR) which imaging modality is best for 275 
diagnosis/staging and what technical factors are important? 276 
• Should biomarkers (serum/fluid) be measured in MPM?  277 
• Is there a staging system for MPM that determines management and predicts outcome? 278 
• What factors determine prognosis and timing of treatment in MPM? 279 
• What are the appropriate cyto-pathological approaches which allow diagnosis and sub-280 
typing of MPM? 281 
• Is the care of patients with suspected/proven MPM improved by discussion at a specialist 282 
MDT? 283 
• Where histological confirmation is either not possible or not definite, what are criteria for a 284 
clinical diagnosis of MPM 285 
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• What is the optimum strategy for the management of pleural fluid in MPM? 286 
• Is there a role for surgery in the management and treatment of patients with MPM? 287 
• Is there a role for systemic anti-cancer treatment in MPM? 288 
• Is there a role for radiotherapy in MPM? 289 
• What treatment/interventions are effective for symptom control in MPM? 290 
• What are the nursing care and information needs for patients with suspected and proven 291 
MPM? 292 
• What is the most effective follow up strategy of patients with MPM? 293 
 294 
The PICOT framework was used to define the scope of the guideline and formed the basis of the 295 
literature search.  The literature search was conducted in December 2014 by York University.  296 
Systematic electronic database searches were conducted in order to identify all papers which may 297 
potentially be included in the guideline.  For each question, the following databases were searched: 298 
Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects 299 
(DARE), Health Technology Assessment Database (HTA), Cochrane Central Register of Controlled 300 
Trials (CENTRAL), MEDLINE and MEDLINE In-Process, EMBASE and PUBMED. 301 
The search was limited to papers published in English.  The searches identified a total of 6173 302 
abstracts.  The full list of abstracts was retained and is kept in an archive.  A second search was 303 
completed in July 2016 to search for relevant papers published between 2014 and 2016, yielding a 304 
further 1038 potentially relevant references.  Additional references were included from personal 305 
collections as appropriate. 306 
2.4 Appraisal of the evidence 307 
An initial screen was completed to remove letters, conference papers, and news articles.  Dr 308 
Woolhouse and Professor Maskell read the remaining abstracts (5129), marked those considered 309 
relevant to the scope of the Guideline and allocated each relevant abstract to a clinical question(s).  310 
950 abstracts were allocated to clinical question(s).  For the second search, the initial screen reduced 311 
the abstracts to 582.  These were all read by Dr Woolhouse and Professor Maskell and 44 were 312 
allocated to clinical question(s). GDG members were allocated to work on the questions in small 313 
groups. 314 
Each abstract was read and at least two members agreed whether the paper was relevant to the 315 
particular guideline section.  Papers were excluded if the following applied:  316 
• If the paper did not answer the clinical question concerned  317 
• If it was a case report of less than 20 patients – however, this was not an absolute cut 318 
off.  Professional judgment was applied and some smaller case reports were considered, 319 
and indeed some case reports of more than 20 patients were excluded. 320 
• If the language of the full paper was not English. 321 
Full papers were obtained for all relevant, or possibly relevant, abstracts.   322 
At least two members of each small group independently appraised each paper using the SIGN 323 
critical appraisal checklists.  An evidence level was assigned to each study using the SIGN 324 
methodology (Table 1). 325 
 326 
Table 1: SIGN Levels of evidence 327 
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1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of 
bias 
1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 
1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias 
2++ High quality systematic reviews of case control or cohort or studies 
High quality case control or cohort studies with a very low risk of confounding or bias and 
a high probability that the relationship is causal 
2+ Well-conducted case control or cohort studies with a low risk of confounding or bias and 
a moderate probability that the relationship is causal 
2- Case control or cohort studies with a high risk of confounding or bias and a significant risk 
that the relationship is not causal 
3 Non-analytic studies, e.g. case reports, case series 
4 Expert opinion 
 328 
Table 2: SIGN Grades of recommendations 329 
A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable 
to the target population; or 
A body of evidence consisting principally of studies rated as 1+, directly applicable to the 
target population, and demonstrating overall consistency of results 
B A body of evidence including studies rated as 2++, directly applicable to the target 
population, and demonstrating overall consistency of results; or 
Extrapolated evidence from studies rated as 1++ or 1+ 
C A body of evidence including studies rated as 2+, directly applicable to the target 
population and demonstrating overall consistency of results; or 
Extrapolated evidence from studies rated as 2++ 
D Evidence level 3 or 4; or 
Extrapolated evidence from studies rated as 2+ 
Good practice points (GPPs) 330 
√ Recommended best practice based on the clinical experience of the guideline 
development group 
 331 
Each relevant paper was read in full by at least 2 members of the GDG and an evidence table entry 332 
was completed for each paper used to support a recommendation/good practice point.  The full 333 
GDG reviewed each section during the regular meetings and consensus was reached.  Evidence 334 
tables are available to view online.   335 
From the outset, it was acknowledged that there would be little high quality evidence for some of 336 
the clinical questions identified.  In this instance, low grade evidence was considered, along with 337 
expert opinion via consensus at the meetings. 338 
The following parameters were used by the GDG to appraise the evidence: 339 
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- How applicable the obtained evidence was in making recommendations for the defined 340 
target audience of this guideline. 341 
- Whether the evidence was generalizable and relevant to the target population for the 342 
guideline. 343 
- Whether there was a clear consistency in the evidence obtained to support 344 
recommendations. 345 
- What the implications of recommendations would be on clinical practice in terms of 346 
resources and skilled expertise. 347 
 348 
Cost-effectiveness was not considered in detail as in-depth economic analysis of recommendations 349 
falls outside of the BTS guideline production process.  However, the GDG were asked to be mindful 350 
of any barriers to implementing the recommendations and GPPs. 351 
Recommendations were graded from A to D as indicated by the strength of the evidence as shown in 352 
Table 2. In line with SIGN guidance, “minus” evidence was considered where necessary, but only in 353 
such instances when there were no published “plus” papers.  In this context, any recommendation 354 
based on this evidence was made Grade D.  GPP were included where research evidence was 355 
lacking, but the GDG felt it was important to highlight practical points which could improve the care 356 
of patients.  Research recommendations were also highlighted and passed to the Chair of the SOCC 357 
on publication of the guideline. 358 
2.5 Planned review and updating of the guideline 359 
In line with BTS policy, this guideline will be reviewed by the SOCC within 5 years of publication and 360 
will then be marked clearly on the BTS website as “Valid”, “Under review” or “Superseded”.   361 
2.6 Declarations of interest 362 
BTS Declarations of Interest forms have been completed by all members for each year they were 363 
part of the GDG.  Details of these forms can be obtained from BTS Head Office.  Declarations of 364 
Interest was a standing item at each GDG meeting. 365 
2.7 Stakeholders 366 
Stakeholders were identified at the start of the process and where appropriate societies and 367 
organisations were contacted and asked to nominate a specific person to join the GDG.  All 368 
stakeholder organisations were notified when the guideline was available for public consultation.  369 
 370 
SECTION 3: CLINICAL FEATURES WHICH PREDICT THE PRESENCE OF MESOTHELIOMA 371 
There is a paucity of evidence exploring clinical features specific for malignant pleural mesothelioma 372 
(MPM). Many of the studies are retrospective questionnaire-based case series which possess a 373 
major inherent recall bias in the diagnosed group making interpretation difficult.  374 
There is consistency in the following risk factors and clinical features:  375 
• Male preponderance is in keeping with occupational exposure[4].  376 
• High risk occupations are consistently, ‘manufacture of non-metallic products’ High risk 377 
occupations are those concerned with the manufacture or non-metallic products which 378 
include production of asbestos sheets, brake and clutch linings, construction/demolition 379 
work, dock and ship yard workers, electricians, plumbers and launderers[5].  380 
• The predicted life time risk of mesothelioma for British men born in the 1940s who did more 381 
than 10 years of work in the following categories, before the age 30 is as below: 5.9% for 382 
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carpenters, 2% for plumbers, electricians and painters, and 0.8% for other construction 383 
workers[6].   384 
• Non-occupational routes of exposure involves: para exposure via a relative or partner 385 
spouse, living in the vicinity of an asbestos factory and environmental exposure (low 386 
level)[4]. There is a higher risk of developing MPM from exposure to amphiboles (brown and 387 
blue asbestos) rather than chrysotile (white asbestos, the most commonly used form) [7].  388 
The mean latency between asbestos exposure and developing the disease is 40 years for 389 
pleural and 46 years for peritoneal mesothelioma[4].  390 
• There are rare familial cases linked to mutation of the breast cancer associated protein 391 
1(BAP-1) gene[8].  392 
 393 
Symptoms:  394 
Chest pain and dyspnoea are the most common presenting symptoms but the relative frequency of 395 
these symptoms is not consistent in different studies. Other symptoms include weight loss, fevers 396 
and sweats [4 9 10]. See Table 3.  397 
Clinical Signs:  398 
Pleural effusion is often present. Other signs are variable (eg palpable lymph nodes)[10]. Right side 399 
predominance of the disease in the order of 1.6:1. might partially reflect the increased pleural 400 
surface area of the right hemithorax[4]. 401 
 402 
Table 3: Symptoms at initial presentation in 90 evaluable cases of MPM[10]. 403 
 404 
Symptom No. of 
cases 
% 
Pain 
Non-pleuritic 
Pleuritic 
62 
56 
6 
69 
Shortness of breath 53 59 
Fever, chills or sweats 30 33 
Weakness, fatigue or malaise 30 33 
Cough 24 27 
Weight loss 22 24 
Anorexia 10 11 
Sensation of heaviness or fullness in chest 6 7 
Hoarseness 3 3 
Early satiety 2 2 
Myalgias 2 2 
Others* 1 each 1 
* other symptoms included aphonia and dysphagia, abdominal distension, sensation of pressure in 405 
right upper quadrant, nausea, bad taste in mouth, perceived tachycardia, and headache. 406 
Usually the first investigation in patients with suspected mesothelioma will be a chest x-ray.  The 407 
NICE Guideline on Investigation and Referral for Suspected Cancer gives guidance on when a chest x-408 
ray should be offered in suspected MPM (Figure 1). 409 
 410 
 411 
Figure 1 provides a summary from the NICE Guideline, outlining where chest X –rays should be 412 
offered. 413 
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Figure 1 :NICE NG 12. Referral criteria for suspected malignant pleural mesothelioma [11]. 414 
 415 
 416 
Evidence statements: 417 
Occupational exposure to asbestos is recalled in the majority of patients with MPM. High-risk 418 
occupations are ship building and construction / demolition work (including boiler repair, and 419 
working as a carpenter or electrician).  Level: 2- 420 
Symptoms are not specific to MPM. Common symptoms at presentation include chest pain and 421 
breathlessness. Less common symptoms at presentation include weight loss, fatigue, fever, and 422 
cough.  Level: 2-   423 
The commonest examination finding at presentation is a pleural effusion (with less than 1 in 10 424 
presenting with lymphadenopathy or clubbing).  Level: 2- 425 
Recommendations: 426 
➢ Do not rule out a diagnosis of MPM on the basis of symptoms and examination findings 427 
alone.  Grade D. 428 
➢ Offer an urgent chest x-ray to patients with symptoms and signs as outlined in NICE GL12  429 
Grade D. 430 
➢ Refer all patients with a chest x-ray suggestive of MPM urgently (via the 2 week wait 431 
suspected cancer pathway in England and Wales).  Consider referral for further investigation 432 
in patients with persistent symptoms and history of asbestos exposure despite normal chest 433 
x-ray.  Grade D. 434 
➢ A thorough occupational history should be taken to cover all occupations throughout life. It 435 
is important to elicit para exposure by exploring details of relative and/or spousal partner 436 
occupations.  Grade D. 437 
 438 
 439 
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SECTION 4: OBTAINING A HISTOLOGICAL DIAGNOSIS 440 
Where ever possible a histological biopsy is required to confirm the diagnosis of mesothelioma. The 441 
best method for obtaining pleural tissue is already covered in the current BTS pleural disease 442 
guidelines. For this reason this topic was not covered in the PICO questions used in our initial 443 
mesothelioma literature search.  The BTS Pleural Disease guideline can be downloaded at the 444 
following website: https://www.brit-thoracic.org.uk/standards-of-care/guidelines/  445 
In summary these BTS pleural guidelines state: 446 
1. In patients with a symptomatic exudative pleural effusion where a diagnostic pleural aspiration is 447 
negative or inconclusive, thoracoscopy (either by local anaesthetic thoracoscopy or video assisted 448 
thoracic surgery (VATS)) is suggested as the next choice investigation since the procedure is 449 
relatively uncomplicated and pleurodesis can be performed at the same time if indicated.  450 
2. If  a contrast-enhanced thoracic CT scan of a patient shows a focal area of abnormal pleura (with 451 
or without a pleural effusion) an image-guided cutting needle biopsy has a high yield and low 452 
complication rates. This technique is particularly useful in patients who are unsuitable for 453 
thoracoscopy. 454 
 455 
SECTION 4: STAGING SYSTEMS 456 
The recommendations of the International Mesothelioma Interest Group (IMIG) [12]  were adopted 457 
in the current (7th 8th Edition) of the AJCC/UICC Staging Manual (see figure 2).  This staging system 458 
was originally derived following expert consensus, rather than from data. Data from surgical series 459 
around the world were combined following International Association for the Study of Lung Cancer 460 
(IASLC) Staging Committee initiatives from 2007 onwards. The IASLC Staging and Prognostic Factors 461 
Committee then established the Mesothelioma Staging Project (MSP) in 2011. This is an 462 
international initiative analysing comprehensive data. Initial analysis of retrospective data from 3101 463 
cases has been reported [13].  Data have now been entered into a second phase of the MSP and 464 
analyses are awaited. 465 
The vast majority of cases entered into the MSP, as summarised in 2012, were surgical (all but 84 of 466 
3101).  Even so, it was accepted that there are inadequacies of current staging, especially 467 
differentiating T1 vs T2, Stages I vs II and the groups of N staging. Greater detail of T and N 468 
descriptors was incorporated into the second phase of data collection within the IASLC MSP. It is 469 
expected that the 8th edition of the AJCC/UICC staging manual will be include a greater number of 470 
non-surgical cases. 471 
In 2016 The International Association for the Study of Lung Cancer (IASLC) International Staging 472 
Committee published proposals for the revisions of the T, N and M descriptors for the eighth edition 473 
of the TNM classification of MPM [14].  This was an international, multi-institutional cohort study. 474 
The study population was patients with newly diagnosed (cytologically or histologically) MPM. 475 
Information was collected on the extent of disease, demographic characteristics, comorbidities, 476 
treatment, and survival.  The dataset included data on 1987 patients with pathologically confirmed 477 
MPM from 29 centres on four continents. These comprised of 509 cases with only clinical staging 478 
information, 836 cases with only pathological staging information (i.e. surgical staging), and 642 479 
cases with both clinical and pathological information available. Survival was examined for T, N and M 480 
categories according to the seventh edition staging system. Categories were then modified where 481 
appropriate to improve prognostic performance. Clinical and pathological T1a and T1b were 482 
combined into a single T1 classification. Clinical and pN1 and pN2 categories were collapsed into a 483 
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single N category comprising ipsilateral, intrathoracic nodal metastases (N1). Nodes previously 484 
categorized as N3 were reclassified as N2. M category remained unchanged (see figure 2). The 485 
proposed TNM groupings are shown in figure 3. Figure 4 shows the survival curves for each of the 486 
new TNM stage groupings. The prognostic performance comparisons for each stage demonstrated 487 
statistically significant hazard ratios for stage IB versus IA, stage IIIA versus II, and stage IV versus IIIB. 488 
The Brigham and Women’s Hospital Group proposed an alternative system to the AJCC/UICC staging 489 
system [15]. The alternative system is based on patients undergoing extrapleural pneumonectomy, 490 
but this has not been accepted widely nor proposals from it included in AJCC/UICC staging group.  491 
The 2016 National Mesothelioma Audit reported that only 42% of MPM patients diagnosed in 2014 492 
had stage recorded [1].  493 
 494 
 495 
 496 
 15 
Post SOCC draft 29/08/2017 
Figure 2: 8 7th edition AJCC/UICC staging for malignant pleural mesothelioma497 
 498 
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Figure ? : Overall survival accoding to best stage (proposed eighth edition). 499 
 500 
Permission to reproduce the table/figures is being sought and the referencing/acknowledgement 501 
will be updated 502 
 503 
Evidence statements: 504 
The proposed eighth edition of the IASLC TNM staging system predicts survival in surgically and non-505 
surgically treated MPM patients. Level 3 506 
The role of TNM staging in non-surgical patients is unclear.  Level 3 507 
Recommendation: 508 
➢ Record staging of MPM according to the version 8 of the IASCL staging proposals. Grade D. 509 
➢ Consider staging MPM according to the latest version of the AJCC/UICC staging manual to 510 
aid stratification for clinical trials and to allow comparison of outcomes with the literature. 511 
Grade D. 512 
 513 
SECTION 5: IMAGING MODALITIES FOR DIAGNOSING AND STAGING 514 
The literature search revealed a large volume of evidence assessing the role of several imaging 515 
modalities in the diagnosis and staging of Malignant Pleural Mesothelioma (MPM). The use of 516 
ultrasound, computed tomography (CT), positron emission tomography (PET) and positron emission 517 
tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI) were all 518 
included in the literature review.   519 
A large number of the studies were conducted in mainland Europe or North America. Only a small 520 
number of studies were from the UK.  The imaging characteristics of MPM are likely to be similar 521 
across the world and the demographic profile of patients included is similar to that of patients in the 522 
UK (male predominance, mean age >50years). Therefore the evidence was considered applicable to 523 
the UK population.  524 
 525 
Evidence on diagnostic imaging 526 
The majority of diagnostic evidence evaluates the role of imaging in differentiating benign from 527 
malignant pleural disease in general, rather than from MPM specifically. Numerous studies have 528 
demonstrated the utility of CT, PET-CT and MRI in the assessment of patients with suspected pleural 529 
malignancy [16]. These studies provide clear guidance on standard morphological characteristics of 530 
pleural malignancy using CT and MRI [17-20] and are summarised in Table 4 along with reported 531 
sensitivities and specificities [21-25].    532 
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Pleural malignancy is typically unilateral. Bilateral involvement is rare, accounting for as few as 3% of 533 
cases [18]. In 94% of cases of pleural malignancy there is a pleural effusion on the affected side. 534 
However, differentiation between MPM and metastatic pleural malignancy can be challenging. The 535 
presence of lung parenchymal involvement or mediastinal or hilar lymph node enlargement may 536 
help point towards metastatic pleural disease [24]. While the presence of pleural plaques is an 537 
indicator of prior asbestos exposure it is not a marker of malignancy per se and effusions can be 538 
found in this context as a result of benign asbestos-related pleural effusion.  539 
Table 4: Diagnostic accuracy of different imaging modalities for diagnosing malignant vs benign 540 
pleural disease. 541 
Morphology Imaging Modality Sensitivity (%) Specificity (%) 
Pleural thickening 
>1cm  
CT 
US 
35 – 47  
42 (95% CI 26 – 61%) 
64 – 94  
95 (95% CI 74 – 99%) 
Pleural nodularity CT 
MRI 
US 
37 – 48  
48 
42 (95% CI 26 – 61%) 
86 – 97  
86 
100 (95% CI 82 – 
100%) 
Infiltration of the 
chest wall and/or 
diaphragm 
CT 
MRI 
17 – 29 
44 
100 
100 
Mediastinal pleural 
involvement 
CT 
MRI 
70 – 74 
77 
83 – 93 
93 
Interlobar fissure 
nodularity 
CT 10 100 
PET-CT can be used to provide useful functional information additional to morphology. Typically, 542 
areas of abnormal malignant pleural thickening have elevated maximal standardised uptake values 543 
(SUVmax) [26 27].  Thus, using a SUVmax threshold of >2.0 has been found to accurately 544 
differentiate malignant from benign pleural disease with a sensitivity of 88 – 100% and specificity of 545 
88 – 92% [28-30]. In a meta-analysis of 11 PET-CT studies this technique had a pooled sensitivity of 546 
95% (95% CI 92 – 97%) and specificity 82% (95% CI 76 – 88%) for differentiation of malignant from 547 
benign pleural disease [31]. Causes of false negatives include: small volume tumours and those with 548 
a low proliferative index, for instance early stage epithelioid mesothelioma. In addition, false 549 
positives may result from inflammatory diseases, tuberculous pleurisy, parapneumonic effusions and 550 
prior talc pleurodesis. One study, which included patients with prior talc pleurodesis, reported 551 
significantly lower specificity in comparison to other studies (specificity 35.3%), as a result of the 552 
high number of false positives in this group [32].   553 
Studies using MRI have highlighted its potential in distinguishing benign from malignant pleural 554 
disease.  Malignant pleural thickening tends to show inhomogenous hyperintensity on proton-555 
density T2-weighted images and enhancement on T1-weighted images following gadolinium 556 
injection, in contradistinction to benign disease that is of low signal on both sequences.  When these 557 
signal characteristics are combined with morphology and a pleural thickening >1cm the accuracy of 558 
MRI is very high for differentiation of benign from malignant disease with sensitivity of 100% and 559 
specificity of 95% in one study (95% confidence intervals not reported) [33].   More recent studies 560 
have highlighted potential utility for diffusion-weighted MR imaging (DWI-MRI) in differentiating 561 
pleural malignancy from benign pleural disease, with lower Apparent Diffusion Coefficient (ADC) 562 
values being demonstrated in pleural malignancy [34 35]. Coolen et al also performed DWI-MRI in a 563 
study of pleural malignancy and reported that inhomogeneous restriction in diffusion of the 564 
thickened pleura differentiates malignant from benign pleural disease with a sensitivity of 92.5% 565 
(95% CI 84-97% 83.7 – 96.8%) and specificity of 79% (95% CI 62-89% 62.2 – 89.3%) [36].  Gill et al 566 
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demonstrated that patients with epithelioid MPM have a significantly higher ADC value than those 567 
with non-epithelioid MPM and an ADC threshold of 1.1 could differentiate epithelioid MPM from 568 
sarcomatoid MPM with a sensitivity of 60% and specificity of 94% (95% confidence intervals not 569 
reported) [35].  These MRI data appear promising but are yet to be validated prospectively and 570 
importantly their added value in disease with atypical or equivocal CT signs is unclear.   571 
 572 
Evidence on staging  573 
 574 
Seventeen [28 37-52] studies were identified that evaluated the role of various imaging modalities 575 
when staging MPM. One systematic review [53] and 1 meta-analysis [54] were also identified in the 576 
literature. To a degree all imaging modalities are limited in accuracy of staging compared with the 577 
gold standard of post-operative histological staging and mediastinoscopic sampling of lymph nodes.  578 
However, assessment of limitations is made difficult by the relative infrequency of surgical resection 579 
and the use of comparator imaging techniques as the reference point in many of the studies.  580 
Despite the overall benefits of CT scanning when initially assessing patients with suspected 581 
mesothelioma, CT performs poorly when compared against other modalities for staging of MPM.  CT 582 
is particularly poor at assessing T4 stage where assessment of invasion through soft tissue such as 583 
diaphragm and chest wall is required. CT also performs poorly at lymph node staging, particularly 584 
when detecting involved N2 and N3 nodes.  In one study, 37% of the patients were upstaged 585 
following a PET scan [38].  586 
 587 
The role of MRI is limited in staging MPM [37 39 40 42 44 45 51]. However, MRI does perform better 588 
than CT, where tumour-soft tissue delineation is required. For example, MRI has a sensitivity and 589 
specificity of 87.5% and 87.5% for stage II disease, and 91% and 100% for stage III disease due to its 590 
superiority in detecting invasion into or through chest wall, endothoracic fascia, diaphragmatic 591 
muscle and mediastinal fat [39]. Table 5 provides a brief summary. 592 
 593 
Table 5: Showing the sensitivity and specificity of CT, MRI and PET-CT in mesothelioma staging [39] 594 
 595 
 596 
It should also be noted that although Plathow et al [39] showed an accuracy of 100% and low inter-597 
observer variability when staging MPM patients with PET-CT, compared to CT and MRI, the results of 598 
other smaller studies are mixed.  599 
 600 
Evidence statements: 601 
Overall reported diagnostic accuracy of CT in the detection of pleural malignancy is 68 - 97%, with 602 
specificity of 78-89%.  Level: 3. 603 
 604 
CT and ultrasound features of malignant pleural disease include pleural thickening >1cm, nodular 605 
pleural thickening, mediastinal pleural thickening and interlobar fissural nodularity.  Level: 3. 606 
 607 
Features favouring MPM over metastatic pleural malignancy are the presence of pleural plaques, 608 
involvement of the interlobar fissure and the absence of lung parenchymal involvement.  Level: 3. 609 
 610 
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Overall reported diagnostic accuracy of PET-CT in the detection of pleural malignancy – sensitivity 611 
88-95%, specificity 35-100%.  Level: 2+. 612 
 613 
False positives at PET-CT are common in TB pleuritis, inflammatory disorders of the pleura and 614 
previous talc pleurodesis.  Level: 3. 615 
 616 
Overall reported diagnostic accuracy of MRI in the detection of pleural malignancy – sensitivity 60-617 
100%, specificity 73-95%.  Level: 2-. 618 
 619 
CT has limited accuracy for staging MPM using current staging systems.  Level: 3. 620 
 621 
MRI is better than CT at detecting invasion through diaphragm and T3 disease (invasion through 622 
muscle, bone, mediastinal fat) but has limited sensitivity in nodal staging.  Level: 3. 623 
 624 
Integrated PET-CT has the highest accuracy for staging MPM. It has better sensitivity across all three 625 
criteria T, N and M compared to CT and MRI. Level: 2+. 626 
Recommendations: 627 
➢ Offer staging CT thorax with contrast (optimised for pleural evaluation) as the initial cross-628 
sectional imaging modality in the evaluation of patients with suspected MPM.  Grade D.   629 
 630 
➢ Use of PET-CT for aiding diagnosis of MPM is not recommended in patients who have had 631 
prior talc pleurodesis and caution should be employed in populations with a high prevalence 632 
of TB.  Grade D. 633 
 634 
➢ In patients where differentiating T stage will change management consider MRI.  Grade D. 635 
 636 
➢ In patients where excluding distant metastases will change management, offer PET-CT.  637 
Grade D. 638 
 639 
 640 
SECTION 7: PATHOLOGICAL DIAGNOSIS 641 
A diagnosis of MPM can be challenging because the tumour has a wide range of morphological 642 
appearances and may mimic many other epithelial or sarcomatoid malignancies.  The best method 643 
for obtaining pleural tissue is already covered in the current BTS pleural disease guidelines. For this 644 
reason this topic was not covered in the PICOT questions used in our initial mesothelioma literature 645 
search.  The BTS Pleural Disease guideline can be downloaded at the following website: 646 
https://www.brit-thoracic.org.uk/standards-of-care/guidelines/  647 
In summary these BTS pleural guidelines states: 648 
1. In patients with a symptomatic exudative pleural effusion where a diagnostic pleural aspiration is 649 
negative or inconclusive, thoracoscopy (either by local anaesthetic thoracoscopy or video assisted 650 
thoracic thoracoscopic surgery (VATS)) is suggested as the next choice investigation since the 651 
procedure is relatively uncomplicated and pleurodesis can be performed at the same time if 652 
indicated.  653 
2. If  a contrast-enhanced thoracic CT scan of a patient shows a focal area of abnormal pleura (with 654 
or without a pleural effusion) an image-guided cutting needle biopsy has a high yield and low 655 
complication rates. This technique is particularly useful in patients who are unsuitable for 656 
thoracoscopy. 657 
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The morphological features of MPM are well described elsewhere in the WHO classification of 658 
pleural tumours[55], and the guidelines of the International Mesothelioma panel [56],and are 659 
beyond the scope of this guideline.  The importance of histological subtyping of MPM is highlighted 660 
in the national mesothelioma audit report which demonstrates that non-epithelioid histology was 661 
associated with significantly shorter overall survival in this cohort [1].  Table 6 highlights the main 662 
subtypes of mesothelioma and the differentce morphological features that might be present within 663 
each group. 664 
Table 6: Mesothelioma subtypes 665 
Epithelioid Bisphasic Sarcomatoid 
 
Tubulopapillary Any combination Cellular storiform 
Clear cell  Desmoplastic 
Adenomatoid  Leiomyoid 
Solid  Chondroid 
Small cell  Lymphohistiocytoid 
Pleomorphic   
The literature search identified 176 papers related to the use of ancillary techniques to improve the 666 
diagnosis of malignant mesothelioma (see Appendix 2 for full list of pathology papers). Several were 667 
rejected due to study age, the applicability of the diagnostic tests, small numbers of cases, or an 668 
inability to extract data, resulting in 70 papers being selected for review. All were retrospective case 669 
series. Case numbers varied greatly, from 23 up to 596 cases, and were often very heterogeneous 670 
case mixtures. Immunohistochemistry (IHC) was by far the most frequently considered ancillary 671 
diagnostic technique. Other approaches used included electron microscopy, chromosomal analysis, 672 
microRNA expression, DNA methylation, mRNA expression array, fluid chemistry assay, 673 
cytofluorimetry, flow cytometry, and insitu hybridization.  674 
 675 
The quality of the evidence reviewed was highly variable.  Some of the papers were unique 676 
descriptions of unusual diagnostic approaches without comparators.  In some studies the origin of 677 
the tumour tissue was not clear and others used autopsy material. Many of the older studies, 678 
especially those published prior to 1990, use clones of primary antibody or other 679 
immunohistochemical techniques that are no longer used or available.  More recent studies typically 680 
used contemporary reagents that are available and applicable in the UK.  681 
Summary of individual immunohistochemistry evidence 682 
A large number of IHC markers have been reviewed and are summarised in the Table 7 below, with 683 
sensitivity and specificity values where available. It should be noted that the sensitivity and 684 
specificity of many of these markers are reduced in sarcomatoid MPM, which frequently does not 685 
express any of the typical ‘mesothelial’ markers. In this scenario, expression of keratins may be the 686 
only demonstrable feature, which is helpful but non-specific. Additionally, discriminating malignant 687 
from benign mesothelial proliferations is not reliable using IHC markers.  688 
Table 7: Summary of IHC markers 689 
Marker Immunoreactivity 
for mesothelioma 
Specimen Sensitivity (%) Specificity (%) 
Calretinin Positive staining Histological 89 – 100 
(Refs[57],[58-72] 
61 – 95 
(Refs [57-72] 
Thrombomodulin Positive staining Histological 
 
 
 
 
52 – 100 
 (Refs [57-59 61-
63 65 69 73-81] 
 
 
56 – 98 
(Refs [57-59 61-
63 65 69 73-81] 
 
36 – 47.5 
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Cytological 67 – 86 
(Refs [77 78] 
(Refs [77 78] 
CK5/6 Positive staining Histological 89 – 100 
(Refs [57-60 62 
65 82] 
58 – 97 
(Refs [57-60 62 
65 82] 
MOC31 Negative staining Histological 
 
 
Cytological 
89 – 94 
(Refs [57 60 66 
83] 
88  
(Ref [84] 
86 – 90 
(Refs [57 60 66 
83] 
76  
(Ref [84] 
BerEp4 Negative staining Histological 
 
 
 
Cytological 
84 – 97 
(Refs [57 61 62 66 
67 76 79 83 85] 
71 – 84  
(Refs [77 84 86 
87] 
65 – 100  
(Refs [57 61 62 66 
67 76 79 83 85] 
83 – 100  
(Refs [77 84 86 
87] 
CEA Negative staining Histological 
 
 
 
Cytological 
90 – 100 
(Refs [57 58 61-
63 66-68 74 76 83 
85 88 89] 
71 – 100 
(Refs [77 84 86 
87] 
53 – 97  
(Refs [57 58 61-
63 66-68 74 76 83 
85 88 89] 
42 – 100  
(Refs [77 84 86 
87] 
TTF-1 Negative staining Histological 93 – 100  
(Refs [58 62 66 68 
90 91] 
53 – 77 
(Refs [58 62 66 68 
90 91] 
CAM 5.2 Positive staining Histological 97 – 100 
(refs [58 66 67 71 
76 85] 
0 – 1.5 
(refs [58 66 67 71 
76 85] 
EMA Positive staining 
(cell membrane) 
Histological 
 
 
Cytological 
74.5 – 90  
(Refs [58 61 62 64 
66 76 85 92] 
58 – 78  
(Refs [77 86 87] 
7 – 87  
(Refs [58 61 62 64 
66 76 85 92] 
8 – 99  
(Refs [77 86 87] 
Leu-M1 Negative staining Histological 
 
Cytological 
94 – 100  
(Refs [67 74 85] 
86 
(Refs [84 86] 
53 – 77  
(Refs [67 74 85] 
65 
(Refs [84 86] 
Vimentin Positive staining Histological 
 
 
Cytological 
60 – 85  
(Refs [61 74 76 85 
88] 
79 – 84  
(Refs [77 86] 
64 – 98  
(Refs [61 74 76 85 
88] 
38 – 50  
(Refs [77 86] 
HBME-1 Positive staining Histological 
 
 
 
Cytological 
59 – 100   
(Refs [58 61 63 67 
73 76 79 81 83 
93] 
71 – 89  
(Refs [77 78] 
28 – 76  
(Refs [58 61 63 67 
73 76 79 81 83 
93] 
36 – 52  
(Refs [77 78] 
WT-1 Positive staining Histological 72 – 91 
(Refs [58-60 66 
88 – 100  
(Refs [58-60 66 
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94] 94] 
CD15 Negative staining Histological 68 – 95  
(Refs [58 60-63 
76] 
73 – 100  
(Refs [58 60-63 
76] 
B72.3 Negative staining Histological 90 – 100  
(Refs [58 62 74 79 
83 85] 
4.2 – 90  
(Refs [58 62 74 79 
83 85] 
BG8 Negative staining Histological 83 – 94 
(Refs [58 94] 
88.5 – 98 
(Refs [58 94] 
Desmin Positive staining Histological 45 – 90  
(Refs [85 92] 
85 – 100  
(Refs [85 92] 
p53 Positive staining Histological 45 – 95  
(Refs [64 92 95] 
47 – 100  
(Refs [64 92 95] 
GLUT-1 Positive staining Histological 58 – 100 
(Refs [96 97] 
100 
(Refs [96 97] 
CD90 Positive staining Histological 73 
(Ref [98] 
82 
(Refs [98] 
Claudin-4 
 
Negative staining Histological 100 
(Ref[99] 
99 
(Ref[99] 
D-240 Positive staining Histological 72.5 
(Ref [100] 
93.5 
(Ref [100] 
 690 
 691 
Additional Techniques 692 
Wu et al [101] examined p16 FISH to discriminate reactive from malignant mesothelium in 60 693 
patients. Hemi or homozygous deletion of p16 was not seen in fibrous pleurisy (FP) but was detected 694 
in 66.7% of epithelioid MPM, 87.5% of biphasic MPM and 100% of sarcomatoid cases, highlighting 695 
potential utility in the differentiation of MPM from fibrinous pleurisy.  Hida et al [102] performed 696 
BAP1 and p16FISH in 40 cases of MPM and 20 cases of inflammatory pleuritis.  All inflammatory 697 
cases and only 3 mesothelioma cases were negative for both.  The presence of BAP1 and or p16FISH 698 
can may therefore be helpful in differentiating MPM from benign mesothelial proliferation. 699 
Diagnosis in Cytology 700 
This remains a controversial subject. The reliability of an MPM diagnosis on effusion cytology is 701 
highly variable, (sensitivity ranging from 16-73%, Walters 2011[103], Segal 2013 [104]) and is very 702 
much dependent upon cytologist experience.  Some centres will send slot clot/cell block sections for 703 
the homozygous deletion of the 9p21 band (p16) which can increase diagnostic certainty. 704 
Evidence statements: 705 
Glut1 immunohistochemistry and p16FISH have potential for discriminating benign from malignant 706 
mesothelium. Level 3. 707 
The sensitivity of pleural fluid cytology for the diagnosis of MPM is highly variable and is dependent 708 
on the cytologist’s experience. Level 3. 709 
Positive immunohistochemistry markers for MPM include calretinin, thrombomodulin, CK5/6, 710 
CAM5.2, EMA, Vimentin, GLUT-1, HBME-1, WT-1, P53. Overall sensitivity is 45 – 100%.  Level 3. 711 
Negative immunohistochemistry markers for MPM include Ber-Ep4, MOC-31, CEA, Leu-1, CD15, TTF-712 
1, B72.3. Overall specificity is 53 – 100%.  Level 3. 713 
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A combination of 2 positive mesothelial markers and 2 negative adenocarcinoma markers increases 714 
diagnostic accuracy.  Level 3. 715 
Diagnostic accuracy of immunohistochemistry markers is reduced in sarcomatoid MPM.  Level 3. 716 
Accurate subtyping of immunochemistry markers is reduced in sarcomatoid MPM. Level 3. 717 
Glut1 immunohistochemistry and p16 FISH have potential for discriminating benign from malignant 718 
mesothelium.  Level 3. 719 
The sensitivity of pleural fluid cytology for the diagnosis of MPM is highly variable and is dependent 720 
on the cytologist’s experience.  Level 3. 721 
Recommendations: 722 
➢ Immunohistochemistry is recommended for the differential diagnosis of MPM in both biopsy 723 
and cytology type specimens.  Grade D. 724 
➢ A combination of at least two positive mesothelial (Calretinin, Cytokeratin 5/6, Wilms 725 
Tumour 1, D-240) and at least two negative adenocarcinoma immunohistochemical markers 726 
(TTF1, CEA, Ber-EP4) should be used in the differential diagnosis of MPM. (Markers listed in 727 
likely order of value).  Grade D. 728 
➢ Do not rely on cytology alone to make a diagnosis of MPM unless biopsy is not possible or 729 
not required to determine treatment due to patient wishes or poor performance status. 730 
Grade D. 731 
➢ Pathologists should report the histological subtype of MPM in all cases. Grade D. 732 
Good Practice Points: 733 
✓ Biopsies from patients with suspected MPM should be reviewed by a pathologist 734 
experienced in the diagnosis of MPM and a second opinion should be sought if there is 735 
uncertainty over the diagnosis. 736 
SECTION 7: USE OF BIOMARKERS 737 
The literature search revealed a large volume of evidence, exploring different biomarkers that may 738 
have a role in MPM. Literature on at least 20 markers tested in serum, plasma, pleural fluid and 739 
exhaled breath were reviewed. A number of markers were assessed in exploratory studies with no 740 
further validation, and such markers have not been considered further given the lack of validation 741 
studies.  742 
Several markers such as Mesothelin, Fibulin-3, Osteopontin and Megakaryocyte potentiating factor 743 
(MPF) have been extensively studied internationally. Individual studies and controlled meta-analyses 744 
specifically looking at these markers were identified and reviewed. Significant heterogeneity was 745 
noted between study populations. In particular, there was wide variability in comparator groups and 746 
disease prevalence. For example, comparator groups include normal controls, asbestos exposed well 747 
individuals, patients with benign effusions, and patients with non-mesothelioma malignant 748 
effusions. In some areas, the prevalence of mesothelioma in the sampled population was above 749 
30%, in others less than 5%. The cut off value for markers varied in most studies. 750 
Although most studies included sarcomatoid mesothelioma, this made up only a small proportion of 751 
the overall cohort or of any single study. 752 
 753 
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Evidence on diagnostic markers: 754 
The most robust body of evidence at present for diagnosis of MPM is for Soluble Mesothelin Related 755 
Peptides (SMRP) and Osteopontin, as summarised below: 756 
• A meta-analysis by Cui et al [105]  reviewed 28 publications totalling 7550 patients (1562 757 
MPM and 5988 non-MPM patients) which confirmed serum SMRP to have an overall 758 
sensitivity of 60% and a specificity of 81%, with an AUC of 0.734.  759 
• The same review also demonstrated that pleural fluid SMRP has an overall sensitivity of 75%, 760 
specificity 76% and AUC 0.809 (Total number of patients 1506; 460 MPM and 1046 non-761 
MPM) 762 
• Summary sensitivities and specificities for SMRP and Osteopontin -  from 2 meta-analyses by 763 
Hu et al [106], reviewing 6 publications with a total of 906 patients, and Lin et al [107] 764 
reviewing 7 publications with a total of  1096 patients, are shown in the Table 8 below.  765 
  766 
Table 8: Summary sensitivities and specificities for SMRP and Osteopontin 767 
 768 
 769 
 770 
 771 
 772 
 773 
 774 
There were a number of studies on Fibulin-3, representing a smaller body of evidence than that 775 
above for SMRP and OPN. These are summarised in Table 9 below:  776 
Table 9: Summary sensitivities and specificities for Fibulin-3 777 
  Sensitivity Specificity AUC Cut off (ng/ml) 
Pass et al [108] Plasma 100 100 1 32.9 33* 
 Plasma 94.6 95 95.7 96 0.99 52.8 53† 
 Pleural fluid 83.8 84 92.4 0.93 346.01 
Agha et al [109] Serum 88 81.8 0.776 66.5 67 
 Pleural fluid 72.3 80 0.878 150 
Elgazzar et al 
[110] 
Serum 100 96.7 97 0.98 54.3 
 Pleural fluid 90 96.7 97 0.94 520 
Creaney et al 
[111] 
Plasma 22 95 n/a 52 
 Plasma 48 71 0.671 29 
 Pleural fluid 59 52 0.588 346 
Kirschner [112] 
 
Plasma 13.5 14 
12.7 13 
96.6 97 
87.5 88‡‡ 
 29‡ 
 
*Detroit cohort † New York 
cohort 
    
    sensitivity specificity AUC 
SMRP  serum 60 (CI 56-64) 81 (CI 78-83) 0.734 
  pleural fluid 75 (CI 69-80) 76 (CI 71-82) 0.809 
          
OPN serum + plasma 65 (CI 60-70) 81 (78-85) 0.83 
  Serum + Plasma 57 (CI 52-61) 81 (79-84) 0.85 
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‡ Sydney cohort ‡‡Vienna 
cohort 
    
 778 
Markers for disease monitoring and assessment of progression 779 
Sixteen [112-127] papers were reviewed in relation to above. Again, SMRP is the most widely 780 
studied marker but other biomarkers such as Fibulin-3, Osteopontin, Megakaryocyte potentiating 781 
factor (MPF) and Hyaluronic acid (HA) were also assessed. Study populations are heterogeneous 782 
with regards to their management. Disease progression/stability in these studies has in general been 783 
assessed by the use of the modified response evaluation criteria in solid tumours (RECIST).  784 
Overall: 785 
• SMRP shows a positive correlation with tumour bulk [113]. 786 
• In patients who had Extra Pleural Pneumonectomy there was a significant drop in SMRP 787 
levels (on average 54%). Despite the relationship with tumour bulk, there is no significant 788 
correlation with increasing disease stage. 789 
• Mean and median SMRP levels for those with progressive disease showed a significant 790 
difference compared to patients with partial/complete response and stable disease [113]. 791 
• A falling SMRP level between baseline and 2 cycles of chemotherapy was associated with a 792 
longer ‘time to progression’ of disease. Fibulin 3 failed to show a similar relationship [126].   793 
• Low Fibulin 3 at diagnosis is associated with a prolonged survival [112]. 794 
 795 
Outcome prediction 796 
Four studies [122 123 125 126] assessed the independent predictive value of biomarkers on overall 797 
survival in MPM, accounting for the recognised prognostic indicators of histological subtype, age and 798 
performance status. These demonstrate: 799 
• The modified Glasgow Prognostic Score (mGPS = serum, c-reactive protein (CRP) and 800 
albumin level at baseline) and the blood neutrophil to lymphocyte ratio (NLR) are 801 
independent predictors of overall survival (HR 2.6 and 2.0 respectively) [122]  802 
• Pleural fluid hyaluronic acid (HA) level (<225mg/L) is independently associated with overall 803 
survival – RR 0.63 [123] 804 
• Resection specimen staining for smoothened (SMO) transmembrane receptor (HR 1.06) was 805 
an independent predictor of overall survival. [125]  806 
 807 
A fall in SMRP between baseline and an interval of 6-8 weeks (post 2 cycles of chemotherapy) is 808 
predictive of radiographic stability of disease. A falling SMRP level at completion of chemotherapy is 809 
strongly associated with a longer survival [126]. Baseline SMRP was unable to predict survival. Apart 810 
from SMRP in the SWAMP study [126], none of the other markers have been prospectively validated.  811 
Biomarkers for screening  812 
Five studies [128-132] explored the potential role of biomarkers in screening for MPM. All 5 studies 813 
looked at SMRP but 2 studies also looked at Osteopontin, CA-125 and cytokeratin fragment 19 [105 814 
126]. Studies were heterogeneous particularly with regards to the cut off value of SMRP, duration of 815 
follow-up and the patient populations (other cancers/control groups). Despite these differences, 816 
SMRP tended to be higher in those with asbestos-related disorders such as asbestosis or diffuse 817 
pleural thickening, and in renal impairment. One study found SMRP levels are also elevated in other 818 
 26 
Post SOCC draft 29/08/2017 
cancers such as lung, ovarian, pancreatic and endometrial cancer but the populations of patients 819 
with these cancers were small.  820 
Evidence statements: 821 
Diagnosis: 822 
There is no diagnostic biomarker which is able to consistently diagnose MPM with a sensitivity and 823 
specificity above 90%.  Level 2+. 824 
 825 
The diagnostic value of biomarkers in sarcomatoid mesothelioma is lower than that for epithelioid, 826 
but small numbers mean that accuracy of sensitivity and specificity are difficult to derive.  Level 2-. 827 
 828 
Serum SMRP has a relatively high specificity in the diagnosis of MPM across a large number of 829 
studies (81%).  Level 2+. 830 
 831 
Serum and pleural fluid Osteopontin has a relatively high specificity in the diagnosis of mesothelioma 832 
across a modest number of studies (81%).  Level 2++. 833 
 834 
Fibulin-3 shows variable performance in diagnosis of MPM (sensitivity range 22-100%). Level 2+ 835 
Disease response: 836 
SMRP level is correlated with tumour bulk and falls post extra pleural pneumonectomy but baseline 837 
level does not predict pathological stage in mesothelioma.  Level 2+. 838 
In assessing response to therapy, SMRP levels are higher in those with progressive disease compared 839 
to those with partial response, complete response or disease stability.  Level 3. 840 
During chemotherapy, a falling level of SMRP from baseline to interval, or a falling level at 841 
completion of palliative chemotherapy is associated with a longer survival.  Level 3. 842 
 843 
Outcome Prediction: 844 
There is no prospectively validated biomarker which independently predicts overall survival in MPM.  845 
Level 2-. 846 
Markers of inflammation, pleural fluid HA and cell staining patterns may predict survival but further 847 
studies are required to validate this.  Level 2-. 848 
Recommendations: 849 
➢ Do not offer biomarkers in isolation as a diagnostic test in MPM.  Grade B. 850 
➢ Consider biomarker testing in patients with suspicious cytology who are not fit enough for 851 
more invasive diagnostic tests.  Grade B. 852 
➢ Do not routinely offer biomarker testing to predict treatment response or survival.  Grade B. 853 
➢ Do not offer biomarker testing to screen for MPM.  Grade C.   854 
Research Recommendation: 855 
Further research is required to identify biomarkers that reliably predict treatment response within 856 
clinical practice 857 
 858 
SECTION 8: FACTORS DETERMINING PROGNOSIS AND TIMING OF TREATMENT 859 
 27 
Post SOCC draft 29/08/2017 
There is a large body of evidence on this topic in the literature.  The great majority of it is of poor 860 
quality, being retrospective case series. Some of these are taken from patients enrolled into clinical 861 
trials, where the consistency and quality of the data collected is higher.   862 
 863 
A large number of baseline patient variables have been studied seeking prognostic factors.  These 864 
include demographic factors (age, sex, race), disease features (histological sub-type and grade, site 865 
of disease, disease stage using various staging systems), Eastern Co-operative Oncology Group 866 
performance status (PS) or Karnofski performance score (KPS), symptoms (particularly chest pain 867 
and weight loss, usually not further defined), markers of inflammation (total white blood count 868 
(WBC), platelet count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-869 
reactive protein level (CRP)), and blood test markers of systemic disease such as haemoglobin level, 870 
haemoglobin difference from a population ideal value (160 g/L in men, 140 g/L in women), serum 871 
albumin.   872 
Several prognostic scores have been developed for mesothelioma, combining groups of prognostic 873 
variables derived from derivation cohorts of mesothelioma patients and subsequently validated in 874 
different, test cohorts.  The following scores are described in more detail below; the EORTC 875 
prognostic score (EPS), the CALGB score [133-138], the modified Glasgow prognostic score (mGPS) 876 
have been studied retrospectively in a cohort of mesothelioma patients [122],the LENT prognostic 877 
score [139], and a prognostic model using decision-tree analysis was published by Brims and others 878 
in 2016 [140].   879 
 880 
Evidence from very large studies 881 
Three retrospective studies were identified, which included more than 5,000 patients from 882 
population-level registries [141-143]. These consistently demonstrate that increasing age, male sex, 883 
advanced stage and non-epithelioid histology are prognostic of worse overall survival.  Although this 884 
evidence is of low quality, being retrospective, the size of the datasets studied and the absence of 885 
any contradictory evidence increases the confidence in these findings. 886 
 887 
Findings from the National Lung Cancer Audit 888 
In 2015 Beckett and others published data from 8740 mesothelioma cases included in the National 889 
Lung Cancer Audit [3].  This is the largest prospectively collected case series in the literature.  It has 890 
the advantage of reflecting the characteristics of unselected incident cases. In this respect it differs 891 
from the populations of clinical trial recruits who have been used to derive, for example, the EORTC 892 
and CALGB prognostic scores (see below).  Poorer performance status and non-epithelioid histology 893 
were associated with shorter overall survival in this cohort.  Survival by sex is not reported. 894 
 895 
The EORTC Prognostic Score 896 
This was derived by Curran and others in 1998 [134] based on maximum-likelihood parameter 897 
estimates of the prognostic factors retained in a multivariate model derived from a population of 898 
204 patients (89% male) entered into clinical trials of chemotherapy in Europe.  All patients were PS 899 
0-2.  More detail on the score can be found at Appendix 2.  900 
 901 
CALGB prognostic groups  902 
Herndon et al studied prognostic factors in a group of 337 patients with MPM not previously treated 903 
with chemotherapy who were entered into phase 2 trials of chemotherapy [138].  Cox survival and 904 
exponential regression trees were used to determine prognostic importance of pre-treatment 905 
patient characteristics. Terminal nodes were amalgamated to form 6 distinct prognostic sub-groups. 906 
 907 
The derived prognostic groups are complex, and continuous variables are dichotomised differently 908 
for different sub-groups (for example, Hb and WBC).The full score can be seen at Appendix 2.  909 
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Edwards and others validated the CALGB groups in a retrospective study conducted in a UK 910 
population [137].  911 
Meniawy and others have validated the CALGB prognostic group method in a recent, large study in 912 
Western Australia, in a population of patients where 62% received chemotherapy.  This is 913 
considerably higher than the proportion of patients currently receiving chemotherapy for 914 
mesothelioma in the UK and therefore the median survival estimates derived from the validation 915 
study are likely to be considerably better than those observed in the UK. 916 
 917 
The Neutrophil-to-Lymphocyte ratio (NLR) 918 
5 studies have considered the NLR in mesothelioma.  The evidence on the prognostic utility of NLR 919 
was reviewed by Meniawy et al [136].  They concluded that the cut-off value chosen for NLR is 920 
variable, the independent predictive effect inconsistent and the NLR has not been validated in a 921 
prospective study.  More information about the studies can be found at Appendix 2.   922 
 923 
The Modified Glasgow Prognostic Score (mGPS) 924 
The mGPS stratifies cancer patients according to c-reactive protein and serum albumin (see 925 
Appendix 2).  This was found to be an independent predictor of overall survival in MPM in one study 926 
[122] (HR 2.6, 95% CI 1.6-4.2, p<0.001) but has not been the subject of prospective validation. 927 
 928 
Prognostic model using decision tree analysis  929 
Brims and others derived a prognostic model using classification and regression tree analysis from an 930 
unselected population of 482 patients newly diagnosed with MPM in Western Australia, of whom 931 
274 were collected retrospectively and 208 prospectively [140].  Unlike the cohorts used to derive 932 
the CALGB and EORTC models, which were of participants in chemotherapy trials, this paper 933 
included all patients with a confirmed diagnosis of MPM within the inclusion period.  The model was 934 
validated in a cohort of 177 MPM patients prospectively collected in Bristol, UK.  The validation 935 
cohort is likely to be highly representative of typical new patients with MPM presenting in the UK.  936 
The model was used to predict death at 18 months. The variable with the greatest influence upon 937 
survival in the derivation cohort was weight loss, defined as any weight loss considered significant by 938 
the medical team.  The decision tree for classifying patients into prognostic groups in this study is 939 
shown in Table 10 below.  The variables having an influence on prognosis within this model are 940 
histological subtype, weight loss, PS, Hb and serum albumin.   The C-statistic for the derivation 941 
cohort was 0.76 and the sensitivity 94.5% (95% CI 91.4-96.7%) and the specificity 38.2% (95% CI 30.6 942 
– 46.3%).  The positive predictive value for death at 18 months was 76% (95% CI 71.5% - 80.1%).  The 943 
C-statistic for model performance in the validation cohort was 0.68 (95% CI 0.60-0.75). 944 
The model can be found at Appendix 2. 945 
 946 
 947 
Table 10: Brim decision tree classification  948 
Prognostic group Median survival (IQR), 
months, derivation cohort 
Median survival (IQR), 
months, validation cohort 
 
1 34.0 (22.9 – 47.0) N/A 
2 17.7 (11.6 – 25.9) 11.93 (8.53-18.56) 
3 12.0 (6.0 – 20.6) 9.89 (4.84 – 17.81) 
4 7.4 (3.3 – 11.1) 5.68 (3.12-10.84) 
 949 
The LENT score 950 
Clive and others derived the LENT score, for predicting survival in patients presenting with malignant 951 
pleural effusion (MPE) [139]. The LENT score uses pleural fluid LDH (>1500) IU/L, ECOG PS, NLR and 952 
tumour type to calculate a prognostic score (see Appendix 3 for a full description of the scoring 953 
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system).   Data from three large international cohorts of patients were used to study the effect of 954 
the malignant cell-type on survival.  A more detailed analysis of individual prognostic factors was 955 
then undertaken in two prospectively collected UK cohorts of patients presenting with MPE.  One 956 
cohort was used to derive a prognostic score and the second to validate it.  14 pre-defined variables, 957 
recorded at presentation, were studied to ascertain their influence on survival using a multivariable 958 
Cox proportional hazard method.  A prognostic score was then developed using the results of the 959 
international cohort for cell type and the UK cohort multivariable analysis.   960 
 961 
Table 11: Summary of LENT score and median survival 962 
LENT score and median survival 
Risk categories Total score Median (IQR) survival  
Low risk 0-1 319 days (IQR 228-549 days) 
Moderate risk 2-4 130 days (47-467 days) 
High risk 5-7 44 days (22-77 days) 
Patients with moderate-risk and high-risk LENT scores had hazard ratios (95% CI) for mortality of 963 
1.49 (1.03-2.15) and 5.97 (3.58-9.97) compared with those with low-risk LENT scores.  The relation 964 
between LENT score and median survival is shown in the Table 11 above.  965 
 966 
Symptoms 967 
Chest wall pain and weight loss have been studied as prognostic variables [133 136 138].  In 968 
retrospective case series, chest pain was independently associated with poorer OS in all three 969 
studies but has not been subjected to prospective validation.  The findings with respect to weight 970 
loss are inconsistent.  Weight loss was independently predictive of survival in two studies [136 138] 971 
but not in the third [133]. 972 
 973 
 974 
Evidence statements: 975 
 976 
Increasing age, male sex, non-epithelioid histology, advanced stage, and poorer performance status 977 
independently predict poorer survival in MPM.  Level 2+ 978 
 979 
The LENT prognostic score provides an approximate estimate of median survival, at presentation, in 980 
patients presenting with a pleural effusion due to MPM.  Level 2+ 981 
 982 
The EPS and CALGB prognostic groups reliably separate patients into groups with better and worse 983 
overall survival but they have been studied only retrospectively, in patients with better performance 984 
status and treated with chemotherapy in the majority.  Level 2+ 985 
 986 
Markers of inflammation including WBC, platelet count, CRP, serum albumin, PLR and NLR may 987 
predict survival but further studies are required, particularly prospectively, to validate this.  Level 3 988 
 989 
The decision-tree model separated unselected UK patients newly diagnosed with MPM into groups 990 
with differing median survival using variables that are routinely collected in almost all patients.  991 
Level 2+ 992 
 993 
Recommendations: 994 
 995 
➢ Consider calculating a prognostic score in MPM patients at diagnosis, particularly when 996 
entering patients into clinical trials.  Grade D 997 
 998 
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➢ Prognostic scores can provide useful survival information for patients and doctors but should 999 
not be used in treatment decision-making.  Grade D 1000 
 1001 
➢ When calculating a prognostic score use one of the following: 1002 
a. The EORTC prognostic score 1003 
b. The CALGB score 1004 
c. The modified Glasgow Prognostic Score 1005 
d. The LENT score if a pleural effusion is present 1006 
e. The decision tree analysis 1007 
The decision tree analysis scoring systems is likely to be the most useful in routine clinical 1008 
practice.Grade D 1009 
 1010 
 1011 
 1012 
SECTION 9: PLEURAL FLUID MANAGEMENT 1013 
There is poor consistency in the literature concerning the outcome of “pleurodesis success” as it is 1014 
variably defined according to time point, radiology only, combined radiology and need for further 1015 
pleural drainage and by patient reported outcome measures.  1016 
There is also substantial lack of consistency in the analysis of time to event data, with many studies 1017 
reporting proportion of “success” at a given time point in those patients assessable at the time – i.e. 1018 
patients who have died  or are unable to attend follow up are discounted, leading to increasing rates 1019 
of pleurodesis success over time in some studies. 1020 
Rintoul et al directly compared video assisted thoracoscopic (VATS) partial pleurectomy to talc 1021 
(poudrage or slurry).  Although early pleurodesis success, as assessed by chest x-ray reporting, 1022 
appeared high in the VATS partial pleurectomy group, this was not sustained over the study follow 1023 
up period (37% talc vs 59% VATS PP at 1 month, 60% at 3 months in both, 57% talc vs 77% VATS PP 1024 
at 6 months, but 77% talc vs 70% VATS PP at 12 months) [144]. VATS pleurectomy was not 1025 
associated with survival benefit (primary outcome) nor benefits to lung function. VATS partial 1026 
pleurectomy patients had a significantly higher complication rate (31% vs 14%) and longer hospital 1027 
stay (7 days versus 3 days). VATS was associated with slight improvement in quality of life but only 1028 
from the 6 month follow up point onwards and not in all quality of life domains.  1029 
 1030 
Davies et al undertook an RCT comparing indwelling pleural catheter (IPC) insertion with talc slurry 1031 
in patients with symptomatic malignant pleural effusions and found no difference in pleurodesis 1032 
success or patient measured breathlessness [145]. There was a shorter hospital stay with IPC, with 1033 
minimisation by mesothelioma, but only small numbers of MPM cases. 1034 
Fysh et al undertook a large retrospective case series which demonstrated no difference in surgical 1035 
versus “medical” pleurodesis in MPM (28.2% vs 29.7% complete success, 39.7% vs 38.8% partial 1036 
success) [146]. In another retrospective series, Bielsa et al demonstrated worse pleurodesis success 1037 
in mesothelioma (66%) and lung (63%) versus breast (77%) and other (74%). Failure of mesothelioma 1038 
versus metastatic pleural cancer was 2.7 [147].  1039 
 1040 
Two other studies specific to MPM evaluated VATS pleurodesis in non-comparative case series, 1041 
reporting pleurodesis success rates of 81%-98%, but were retrospective, and suffer from selection 1042 
bias and used different pleurodesis definitions [148 149]. Non-MPM specific studies reported 1043 
pleurodesis success rates of 80-86% and did not differentiate mesothelioma from other MPE. One of 1044 
these studies reported performance status rather than pleurodesis success [150-152].  1045 
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 1046 
Evidence statements: 1047 
Pleural effusion due to MPM may have a lower pleurodesis success rate than other malignant 1048 
effusions.  Level  2-. 1049 
No single fluid control technique (Surgical including pleurectomy and VATS, thoracoscopic talc 1050 
poudrage, talc slurry or IPC) has been shown to be superior in terms of patient symptoms or 1051 
pleurodesis success in MPM.  Level  1-. 1052 
 1053 
VATS partial pleurectomy has been shown to be more expensive, associated with greater 1054 
complications and longer hospital stay than talc slurry pleurodesis.  Level  1+. 1055 
 1056 
VATS partial pleurectomy is associated with minor improvement in quality of life versus talc slurry in 1057 
those patients who survive more than 6 months.  Level  1-. 1058 
 1059 
Indwelling pleural catheters and talc slurry pleurodesis have similar patient related outcomes in 1060 
malignant effusion and MPM.  Level  1++. 1061 
 1062 
Recommendations: 1063 
 1064 
➢ Offer either talc (via slurry or poudrage) or indwelling pleural catheters for symptomatic 1065 
pleural effusion in MPM, informed by patient choice.  Grade A. 1066 
➢ Talc slurry or thoracoscopic talc poudrage pleurodesis should be offered to patients with 1067 
MPM in preference to a VATS partial pleurectomy surgical approach for fluid control in 1068 
MPM.  Grade A. 1069 
 1070 
SECTION 10: THE ROLE OF SURGERY  1071 
Surgical resection has been offered to a highly selected subgroup of patients with MPM since the 1072 
1950’s, although its role remains controversial. Surgery can be offered with palliative intent, where 1073 
the aim is debulking of the tumour mass with the aim of controlling pleural fluid, reducing 1074 
pulmonary restriction, or by attempting to achieve a complete macroscopic resection, with the aim 1075 
of improving length and/or quality of life. The International Association for the Study of Lung 1076 
Cancer’s Staging and Prognostic Factors Committee has proposed definitions for surgery, which have 1077 
been adopted for this guidance [153] 1078 
 1079 
1. Partial pleurectomy (PP): partial removal of parietal and/or visceral pleura for diagnostic or 1080 
palliative purposes but leaving gross tumour behind. This may be performed by VAT or with 1081 
thoracotomy.  1082 
 1083 
2. Pleurectomy/Decortication (PD P/D): parietal and visceral pleurectomy to remove all gross tumour 1084 
without resection of the diaphragm or pericardium. 1085 
  1086 
3.  Extended Pleurectomy/Decortication (EPD): parietal and visceral pleurectomy, with the goal of 1087 
complete macroscopic resection, with resection of the diaphragm and/or pericardium as required.  1088 
 1089 
4.  Extrapleural pneumonectomy (EPP): en-bloc resection of the parietal pleura, pericardium, 1090 
diaphragm, lung and visceral pleura 1091 
 1092 
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 1093 
Evidence Review 1094 
95 papers were identified and reviewed, of which 12 were considered in detail [134 144 154-163]. 1095 
There were 2 randomised controlled trials, 4 systematic reviews, 4 prospective observational studies 1096 
and 2 retrospective studies. 1097 
 1098 
Pleurectomy 1099 
A systematic review has been performed of thirty-four studies involving 1916 patients who 1100 
underwent pleurectomy [161]. These included 12 studies on extended PD P/D, 8 studies on PD P/D 1101 
and 14 studies on PP. All the studies were observational with high risk of selection bias. 1102 
Perioperative mortality ranged from 0% to 11% and perioperative morbidity ranged from 13% to 1103 
43%. Median overall survival ranged from 7.1 to 31.7 months and disease-free survival ranged from 1104 
6 to 16 months. 1105 
 1106 
The MesoVATS trial randomised 196 patients with suspected or confirmed mesothelioma (of whom 1107 
175 had mesothelioma) between talc pleurodesis or VATS PP [144].  The primary outcome was 1108 
survival at 1 year, which was 52% (95% CI 41–62) in the VAT-PP group and 57% (46–66) in the talc 1109 
pleurodesis group (hazard ratio 1·04 [95% CI 0·76–1·42]; p=0·81). Surgical complications were 1110 
significantly more common after VAT-PP than after talc pleurodesis, occurring in 24 (31%) of 78 1111 
patients who completed VAT-PP versus ten (14%) of 73 patients who completed talc pleurodesis 1112 
(p=0·019), as were respiratory complications (19 [24%] vs 11 [15%]; p=0·22). Median hospital stay 1113 
was longer at 7 days (IQR 5–11) in patients who received VAT-PP compared with 3 days (2–5) for 1114 
those who received talc pleurodesis (p<0·0001).  1115 
 1116 
 1117 
 1118 
 1119 
Extended pleurectomy Decortication and Extra-pleural pneumonectomy  1120 
 1121 
The Mesothelioma and Radical Surgery (MARS) feasibility study assessed EPP versus no EPP for 1122 
patients with MPM [154]. Patients with pathologically confirmed mesothelioma deemed fit enough 1123 
to undergo trimodal therapy were included. All patients underwent induction platinum-based 1124 
chemotherapy followed by clinical review. After further consent, patients were randomly assigned to 1125 
EPP followed by postoperative hemithorax irradiation or to no EPP. Of 112 patients registered 50 1126 
were subsequently randomly assigned: 24 to EPP and 26 to no EPP. EPP was completed satisfactorily 1127 
in 16 of 24 patients assigned to EPP. Two patients in the EPP group died within 30 days and a further 1128 
patient died without leaving hospital. One patient in the no EPP group died perioperatively after 1129 
receiving EPP off trial in a non-MARS centre. The hazard ratio [HR] for overall survival between the 1130 
EPP and no EPP groups was 1·90 (95% CI 0·92–3·93; exact p=0·082), and after adjustment for sex, 1131 
histological subtype, stage, and age the HR was 2·75 (1·21–6·26; p=0·016). Median survival was 14·4 1132 
months (5·3–18·7) for the EPP group and 19·5 months (13·4 to time not yet reached) for the no EPP 1133 
group. Of the 49 randomly assigned patients who consented to quality of life assessment (EPP n=23; 1134 
no EPP n=26), 12 patients in the EPP group and 19 in the no EPP group completed the quality of life 1135 
questionnaires. Although median quality of life scores were lower in the EPP group than the no EPP 1136 
group, no significant differences between groups were reported in the quality of life analyses.  1137 
 1138 
There has been much discussion around the validity of the MARS trial results. In particular, criticism 1139 
that the study was not powered to detect a survival advantage attributable to EPP and that the 1140 
operative mortality was higher than that of other contemporary series. The MARS trial authors have 1141 
subsequently responded that the EPP mortality in MARS (2 of 19; 10.5%; 95% confidence limits 1142 
1.3%–33.1%) lies within the range reported in a systematic review of 34 studies, including 2320 1143 
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patients, where 30-day mortality ranged from 0% to 11.8% [164]. Furthermore, the authors note 1144 
that the median survival of patients in the EPP arm of MARS of 14.4 months from randomization is in 1145 
keeping with major series in the literature which report median survival times of 10 to 14 months. 1146 
 1147 
Cao et al [159] performed a systemic review of 34 studies with 2462 patients who underwent EPP for 1148 
MPM. All the studies were observational and subject to high risk of selection bias. The median 1149 
overall survival varied from 9.4 to 27.5 months, and 1-, 2-, and 5-year survival rates ranged from 36 1150 
to 83%, 5 to 59%, and 0 to 24%, respectively. Overall perioperative mortality rates ranged from 0 to 1151 
11.8%, and the perioperative morbidity rates ranged from 22 to 82%. Quality of life assessments 1152 
from three studies reported improvements in nearly all domains at 3 months postoperatively. 1153 
Patients who underwent trimodality therapy involving EPP and adjuvant chemoradiotherapy had a 1154 
median overall survival of 13 to 23.9 months. 1155 
 1156 
Two meta-analyses have been performed comparing outcomes following either PD or EPP. All the 1157 
studies included in the analyses were observational with high risk of selection bias.  The meta-1158 
analysis by Taioli et al[165]  included 1512 patients treated by PD and 1391 treated with EPP . There 1159 
was a significantly higher proportion of short-term deaths in the EPP group versus the PD P/D group 1160 
(percent mortality meta estimate; 4.5% vs 1.7%; p < 0.05). There was no statistically significant 1161 
difference in 2-year mortality between the 2 groups, but there was significant heterogeneity. The 1162 
meta-analysis by Cao et al 2014 included 632 patients who underwent EPP and 513 patients who 1163 
underwent EPD [162]. All-cause perioperative mortality was found to be significantly lower after EPD 1164 
compared to EPP (2.9% vs 6.8%; RR, 0.53; 95% confidence interval [CI], 0.31–0.91; p = 0.02; I2 = 0%). 1165 
Perioperative morbidity was also found to be significantly lower after EPD compared to EPP (27.9% 1166 
vs 62.0%; RR, 0.44; 95% CI, 0.30–0.63; p < 0.0001; I2 = 44%). There were insufficient data for this 1167 
meta-analysis to compare the overall survival outcomes between the two treatment arms. 1168 
 1169 
The effects of PD on lung function and quality of life have been assessed in a number of small cohort 1170 
studies. None of these studies compared changes in outcomes with patients who were not selected 1171 
to undergo surgery and so the results must be interpreted with caution. Mollberg et al found that 1172 
quality of life scores did not deteriorate in 28 patients with good performance status (0-1) who 1173 
underwent PD [155]. Bölükbas et al found that the mean forced vital capacity improved from 55% of 1174 
predicted to 69% of predicted (p<0.01) in 16 patients who underwent radical pleurectomy [156]. 1175 
Ploenes et al retrospectively reviewed the outcomes of 25 patients who underwent EPP and 23 who 1176 
had PD [158]. Pulmonary function was not significantly reduced in the PD group postoperatively. In 1177 
the EPP group, the median vital capacity fell from 78% of predicted to 48% predicted (p<0.001). 1178 
Burkholder et al assessed quality of life in 36 patients undergoing PD [157]. Global quality of life 1179 
scores were unchanged in the 17 patients with performance status of 0 and improved in the 19 1180 
patients with performance status of 1 or 2. 1181 
 1182 
A feasibility multi-centre randomised trial comparing extended Pleurectomy/Decortication to no 1183 
surgery (MARS-2 trial) is currently recruiting in the UK [163]. Results from this surgical trial are 1184 
awaited with interest. 1185 
 1186 
 1187 
Evidence statements: 1188 
 1189 
VAT Partial Pleurectomy has no effect on overall survival and results in increased complications and 1190 
longer hospital stay than talc pleurodesis  Level 1+ 1++ 1191 
 1192 
Extra-Pleural Pneumonectomy is potentially harmful to patients does not improve survival when 1193 
added to treatment with chemo-radiotherapy  Level 1+ 1194 
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 1195 
Extended Pleurectomy / Decortication may result in lower perioperative mortality than Extra-pleural 1196 
pneumonectomy.  Level 1- 1197 
 1198 
Quality of life and lung function may not deteriorate in patients selected to undergo pleurectomy 1199 
decortication. Level 2- 1200 
 1201 
Recommendations: 1202 
 1203 
➢ Do not offer VATS Partial Pleurectomy over talc pleurodesis in MPM Grade A 1204 
 1205 
➢ Do not offer Extra-Pleural Pneumonectomy in MPM  Grade B 1206 
 1207 
➢ Do not offer extended pleurectomy decortication outside of a clinical trial  Grade D 1208 
 1209 
Research recommendation: 1210 
 1211 
The role of VATS-PP and EPD in good prognosis patients should be examined further in clinical trials, 1212 
which should include robust measurement of quality of life. 1213 
 1214 
SECTION 11: SYSTEMIC ANTI-CANCER TREATMENT 1215 
Evidence  1216 
The literature search revealed a large volume of evidence assessing the role of systemic treatment. 1217 
Over two hundred articles were obtained from a search. Of these, 69 were not relevant to the 1218 
question.  Papers were excluded if they involved tri-modality therapy or radiotherapy as major 1219 
features in the trial design. This included papers looking at the role of neo-adjuvant or adjuvant 1220 
chemotherapy in the setting of surgery. Papers were excluded if they involved intrapleural 1221 
chemotherapy and photodynamic therapy during as part of surgical therapy.  1222 
Evidence on first-line systemic therapy 1223 
Almost all the first-line studies identified were non-randomised phase II trials. Four large phase III 1224 
randomised trials comparing novel systemic therapy to 'standard' therapy were identified. Two of 1225 
the large randomised trials used a control arm of single-agent cisplatin and one used a control arm 1226 
of active symptom control (ASC). Table 12 summarises phase III trial data. 1227 
 1228 
Table 12: Randomised phase III trials in first-line treatment of MPM 1229 
Trial Year of 
publication 
Treatment arms 
 
OS (months) P-value 
Vogelzang [166] 2003 P/C v C 12.1 vs 9.3 P=0.020 
Van Meerbeeck 
[167] 
2005 R/C v C 11.4 vs 8.8 P=0.048 
Muers [168] 2008 ASC + ctx v ASC 8.5 vs 7.6 P=0.290 
Zalcman [169] 2015 P/C/B v P/C 18.8 vs 16.1 P=0.017 
P= pemetrexed; R=ralitrexed; C =cisplatin; ASC= active symptom control; B= bevcizumab; ctx= 1230 
chemotherapy: OS=overall survival 1231 
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The first large randomised trial (known as EMPHASIS) to be published in patients with MPM 1232 
compared three-weekly intravenous chemotherapy with the anti-folate drug pemetrexed at a dose 1233 
of 500mg/m2 and cisplatin at a dose of 75mg/m2 with a control arm of cisplatin at a dose of 1234 
75mg/m2 [166] .The primary outcome was survival. Secondary outcomes were time to progressive 1235 
disease, time to treatment failure, tumour response rate, and duration of response. 226 patients 1236 
were randomised to pemetrexed/cisplatin, and 222 to cisplatin alone. The median survival time for 1237 
pemetrexed/cisplatin-treated patients was longer than for patients receiving cisplatin alone: 12.1 1238 
months versus 9.3 months, representing a statistically significant difference (p=0.020). The median 1239 
time to progressive disease was significantly longer for patients who received pemetrexed and 1240 
cisplatin as compared with patients who received cisplatin alone (5.7 months v 3.9 months; p = 1241 
0.001). The median time to treatment failure was also significantly longer in the 1242 
pemetrexed/cisplatin arm than in the control arm. The response rates were 41% for 1243 
pemetrexed/cisplatin patients versus 17% in the control group.  1244 
 1245 
Whilst this trial was recruiting the investigators became aware of excessive bone marrow toxicity 1246 
likely due to folate depletion probably caused by pemetrexed. They decided to give all patients, both 1247 
in the trial arm and the control arm, vitamin B12 (by intramuscular injection) and folic acid (by 1248 
tablet) supplementation. Bone marrow toxicity was reduced and vitamin supplementation is now 1249 
standard for all patients treated with pemetrexed. The incidence of nausea, vomiting, fatigue, 1250 
diarrhoea, dehydration, and stomatitis were significantly higher in the pemetrexed/cisplatin arm.  1251 
 1252 
In 2005 a broadly similar randomised controlled trial was published by the European Organisation 1253 
for the Research and Treatment of Cancer (EORTC) [167]. The experimental arm was the antifolate 1254 
drug raltitrexed combined with cisplatin (arm B), with a control group of single-agent cisplatin (arm 1255 
A). Raltitrexed is comparable to pemetrexed in that its main mechanism of action is by inhibiting 1256 
thymidylate synthase thereby preventing the formation of precursor pyrimidine nucleotides. 1257 
Endpoints were overall survival, response rates and quality of life. Patients had to have good 1258 
performance status (WHO 0-2) and adequate haematological, renal and hepatic function. Two 1259 
hundred and fifty patients were randomised: 80% were male and the median age was 58. The main 1260 
grade 3 or 4 toxicities observed were neutropenia and emesis, reported twice as often in the 1261 
combination arm. Among 213 patients with measurable disease, the response rate was 13.6% (arm 1262 
A) versus 23.6% (arm B; P = 0.056). Median overall and 1-year survival in arms A and B were 8.8 (95% 1263 
CI, 7.8 to 10.8) v 11.4 months (95% CI, 10.1 to 15), respectively, and 40% v 46%, respectively (P = 1264 
0.048).  1265 
 1266 
A large cooperative group based in the UK led by Muers organised a large three-arm randomised 1267 
clinical trial known as MS01[168]. Patients were randomised into 3 groups. Group 1: active symptom 1268 
control (ASC). The essential elements of ASC were defined as regular follow-up in a specialist clinic; 1269 
structured physical, psychological, and social assessments at every clinic visit; rapid involvement of 1270 
additional specialists; and parallel nursing support. Patients could receive, as required, steroids, 1271 
analgesic drugs, appetite stimulants, bronchodilators, or palliative radiotherapy, Group 2: ASC plus 1272 
mitomycin, cisplatin and vinblastine chemotherapy (MVP), or Group 3: ASC plus vinorelbine 1273 
chemotherapy. A total of 840 patients (280 in each group) were needed to detect an improvement 1274 
of 3 months survival, however due to slow accrual the trial design changed to a two-group 1275 
comparison by combining the two chemotherapy groups. The two-group design needed a total of 1276 
420 patients (140 ASC, 280 ASC plus chemotherapy) to reliably detect an improvement from 9 1277 
months median survival with ASC alone to 12 months with ASC plus chemotherapy. Four hundred 1278 
and nine patients with malignant pleural mesothelioma, from 76 centres in the UK and two in 1279 
Australia, were randomly assigned to ASC alone [n=136]; to ASC plus MVP (four cycles of mitomycin 1280 
6 mg/m2, vinblastine 6 mg/m2, and cisplatin 50 mg/m2 every 3 weeks [n=137]); or to ASC plus 1281 
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vinorelbine (one injection of vinorelbine 30 mg/m2 every week for 12 weeks [n=136]). The results 1282 
showed that, compared with ASC alone, there was no significant survival benefit for ASC plus 1283 
chemotherapy (hazard ratio [HR] 0.89 [95% CI 0.72-1.10]; p = 0.29). Median survival was 7.6 months 1284 
in the ASC alone group and 8.5 months in the ASC plus chemotherapy group. There were no 1285 
between-group differences in four predefined quality-of-life subscales (physical functioning, pain, 1286 
dyspnoea, and global health status) at any of the assessments in the first six months. The trial 1287 
attracted some criticism for the decision to combine the two different chemotherapy arms, thus 1288 
reducing the power to detect a significant difference for the separate regimens [170]. 1289 
A more recent trial reported by Zalcman et al presented data on the addition of bevacizumab to 1290 
pemetrexed and cisplatin chemotherapy for patients with newly diagnosed MPM [169]. The trial, 1291 
called MAPS (Mesothelioma Avastin Cisplatin Pemetrexed Study) was a randomised, controlled, 1292 
open-label, phase 3 trial. Patients aged 18-75 years with unresectable MPM who had not received 1293 
previous chemotherapy, had an Eastern Cooperative Oncology Group performance status of 0–2, 1294 
had no substantial cardiovascular comorbidity, were not amenable to curative surgery, had at least 1295 
one evaluable (pleural effusion) or measurable (pleural tumour solid thickening) lesion with CT, and 1296 
a life expectancy of >12 weeks from 73 hospitals in France. Patients were stratified by histology 1297 
[epithelioid vs sarcomatoid or mixed histology subtypes], performance status score [0–1 vs 2], study 1298 
centre, or smoking status [never smokers vs smokers]) to receive intravenously 500 mg/m² 1299 
pemetrexed plus 75 mg/m² cisplatin with (PCB) or without (PC) 15 mg/kg bevacizumab in 21 day 1300 
cycles for up to six cycles, until progression or toxic effects. The primary outcome was overall 1301 
survival (OS) in the intention-to treat population. 448 patients were randomised to treatment (223 1302 
to PCB and 225 to PC). Overall survival was significantly longer with PCB (median 18·8 months [95% 1303 
CI 15·9–22·6]) than with PC (16·1 months [14·0–17·9]; hazard ratio 0·77 [0·62–0·95]; p=0·0167). 1304 
Overall, 158 (71%) of 222 patients given PCB and 139 (62%) of 224 patients given PC had grade 3–4 1305 
adverse events. More grade 3 events, higher rates of hypertension and more thrombotic events 1306 
were noted with PCB compared with PC. Bevacizumab treatment is not currently available licensed 1307 
for use in the UK and is not available in the NHS. 1308 
An International Expanded Access Program (EAP) led by Santoro followed more than 3000 1309 
mesothelioma patients treated with single-agent pemetrexed or pemetrexed in combination with 1310 
cisplatin or carboplatin [171]. Patients with histologically confirmed MPM, not amenable to curative 1311 
surgery, received pemetrexed 500 mg/m2 in combination with either cisplatin 75 mg/m2 or 1312 
carboplatin AUC 5, once every 21 days with standard premedication. A total of 1704 chemonaïve 1313 
patients received pemetrexed plus cisplatin (n = 843) or pemetrexed plus carboplatin (n = 861) and 1314 
were evaluated for safety. The efficacy evaluable population consisted of 745 patients in the 1315 
pemetrexed plus cisplatin group and 752 patients in the pemetrexed plus carboplatin group for 1316 
whom physician-reported tumour response was available. The pemetrexed plus cisplatin group 1317 
demonstrated a response rate of 26.3% compared with 21.7% for the pemetrexed plus carboplatin 1318 
group, with similar 1-year survival rates (63.1% versus 64.0%) and median time to progressive 1319 
disease (7 months versus 6.9 months). Based on these data pemetrexed plus and carboplatin is 1320 
generally considered an acceptable alternative two-drug first line option especially for patients 1321 
deemed unfit for cisplatin, although the data on which this practice is based are not from a 1322 
randomised controlled trial. 1323 
Second line systemic treatments in MPM 1324 
Buikhuisen et al undertook a systematic review of 10 studies reporting on 1251 patients treated with 1325 
second-line chemotherapy in MPM [172]. The majority of studies were phase II with only two phase 1326 
III randomised trials. The authors concluded that only a limited number of randomised studies with 1327 
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combination therapy had been conducted. The authors suggested the following as second line 1328 
treatment options for patients with MPM: ‘single agent vinorelbine or pemetrexed are acceptable 1329 
second line agents for patients relapsing after a first line platinum combination regardless of 1330 
whether or not pemetrexed was used in the first line setting’. They also stated that the ‘low 1331 
reported activity of the drugs in second line warrants referral of fit patients to participate in clinical 1332 
trials’. 1333 
 Jassem et al compared the efficacy and safety of pemetrexed and best supportive care in patients 1334 
with MPM after first-line chemotherapy (excluding pemetrexed) [173]. Of the 243 patients included, 1335 
18.7% of the 143 patients receiving pemetrexed showed a partial response but the median overall 1336 
survival was not significantly different between the two groups.  1337 
The VANTAGE-014 study compared vorinostat, an oral histone deacetylase inhibitor, with placebo in 1338 
661 MPM patients who had previously received one or two systemic regimens [174]. Median overall 1339 
survival for vorinostat was 30·7 weeks (95% CI 26·7–36·1) versus 27·1 weeks (23·1–31·9) for placebo 1340 
(hazard ratio 0·98, 95% CI 0·83–1·17, p=0·86).  1341 
Anti-PD1 immune checkpoint therapy may have  has potential for the treatment of mesothelioma. 1342 
Approximately 40 percent of tumours of patients express PDL1, which is associated with non-1343 
epithelioid histology and worse outcome for high expressing tumours [175]. Keynote 28 is the first 1344 
phase Ib trial to report on the activity of pembrolizumab in patients with pleural mesothelioma and 1345 
enrolled 25 patients with harbouring PDL1 positive tumours [176].  This study showed a 20% 1346 
response rate with durability lasting on average 12 months. Stable disease was 52% giving a disease 1347 
control rate (DCR) of 72%. Median overall survival was 18 months.  In summary, emerging data 1348 
suggests anti-PD1 or PDL1 immunotherapy, exhibits efficacy in mesothelioma, however randomised 1349 
trials will be needed to confirm the incremental benefit and value. In this regard, the CRUK CONFIRM 1350 
phase III trial is currently randomising patients 2:1 to nivolumab versus placebo [NCT03063450] 1351 
Evidence statements 1352 
 1353 
For patients with MPM with good performance status first-line therapy with cisplatin and 1354 
pemetrexed and bevacizumab leads to longer survival than cisplatin and pemetrexed alone. 1355 
However, bevacizumab is not licensed for this use in the UK. Evidence level 1 + + 1356 
 1357 
For patients with MPM with good performance status first-line chemotherapy with cisplatin and 1358 
pemetrexed leads to longer survival than cisplatin alone. Evidence level 1 + + 1359 
 1360 
For patients with MPM with good performance status first-line chemotherapy with cisplatin and 1361 
raltitrexed leads to longer survival than cisplatin alone. Evidence level 1 + + 1362 
 1363 
The combination of mitomycin, cisplatin and vinblastine or single agent vinorelbine did not 1364 
demonstrate survival benefit over active symptom control. Evidence level 1 +  1365 
 1366 
Carboplatin in combination with pemetrexed is a safe and effective alternative to cisplatin in 1367 
combination with pemetrexed. Evidence level 3 1368 
 1369 
Second line pemetrexed does not improve survival in patients previously treated with first line 1370 
chemotherapy regimens that did not include pemetrexed. Evidence level 1+ 1371 
 1372 
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Second line vorinostat does not improve survival in patients previously treated with one or two 1373 
cycles of chemotherapy. Evidence level 1+  1374 
 1375 
 1376 
Recommendations 1377 
➢ Offer patients with MPM with good performance status (0-1) first-line therapy with cisplatin, 1378 
pemetrexed.  Raltitrexed is an alternative to permetrexed. and bevacizumab. Grade A 1379 
 1380 
➢ If bevacizumab is unavailable, offer patients with MPM with good performance status (0-1) 1381 
first-line chemotherapy with cisplatin and pemetrexed.  Raltitrexed is an alternative to 1382 
pemetrexed. Grade A  If the manufacturers seek a UK license for bevacizumab, consider its 1383 
use in addition to cisplatin and pemetrexed as first line therapy for patients with MPM with 1384 
good performance status (0-1). 1385 
 1386 
➢ Do not offer pemetrexed or vorinostat as second line treatment for patients with MPM. 1387 
Grade A. 1388 
 1389 
Good practice points 1390 
 1391 
✓ Where cisplatin is contraindicated, or has adverse risk, offer Ccarboplatin in combination 1392 
with pemetrexed. 1393 
 1394 
✓ First line clinical trials are an appropriate option for patients with good performance status 1395 
and are recommended above any other option for second-line treatment, providing the 1396 
patient is of adequate performance status. 1397 
 1398 
 1399 
 1400 
 1401 
Research Recommendations 1402 
Randomised controlled trials of immunotherapy in MPM. 1403 
Randomised controlled trials of second line therapy in MPM. 1404 
 1405 
Further research as highlighted by the James Lind Alliance is needed in the following areas; 1406 
Immune boosting therapy (eg. anti PD1 and anti PDL1 checkpoint inhibition) 1407 
Further comprehensive genomic profiling of mesothelioma leading to individualised therapy  1408 
The role of second line chemotherapy 1409 
 1410 
Future therapies: Summary of ongoing trials into potential treatments using PD1 inhibitors/anti 1411 
PDL1 in mesothelioma. 1412 
 1413 
Pembrolizumab is an antibody based therapeutic agent that is targeted at the immune inhibitory 1414 
protein programmed death 1 (PD1). This protein engages with, and inhibits T cell mediated immunity 1415 
against cancers, which express foreign antigens by virtue of their mutations which ultimately causes 1416 
of the cancer. By interacting with PD1, pembrolizumab reactivates the immune system by essentially 1417 
removing its camouflage. This leads to the immune system attacking the cancer. This approach has 1418 
been successful across a wide range of cancers and has been heralded as a new paradigm in cancer 1419 
therapeutics. For example, approval internationally has been granted for the use of pembrolizumab 1420 
for the treatment of melanoma, non-small lung cancer, bladder cancers with many other studies 1421 
ongoing, showing promising results. 1422 
 1423 
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The Keynote 28 study investigators (study NCT 02054806) presented clinical trial data at the 2015 1424 
American Association for Cancer Research (AACR). This study showed that pembrolizumab has 1425 
significant activity in patients with mesothelioma associated with a 28% response rate and 76% 1426 
disease control rate. Critically, the expression of the PDL1 (programmed death 1 ligand), a potential 1427 
predictive biomarker for pembrolizumab, was not shown to be associated with efficacy, implying 1428 
that patients could benefit irrespective of the biomarker.  1429 
The European Thoracic Oncology platform (ETOP) are planning a study randomizing pembrolizumab 1430 
against chemotherapy shortly. Another study, Keynote 158 is currently recruiting at a single UK 1431 
centre enrolling patients who will receive single agent pembrolizumab as part of a biomarker 1432 
analysis.  1433 
 1434 
Nivolumab is being evaluated in a single arm trial in the Netherlands, and Cancer research UK is 1435 
supporting the CONFIRM trial, a placebo controlled double blind phase III trial of nivolumab in 1436 
relapsed mesothelioma due to open in 2017. Another CRUK study is evaluating combination 1437 
FAK/PD1 inhibition in mesothelioma.  1438 
The anti PDL1 agent avelumab is being evaluated in mesothelioma (JAVELIN basket study), and the 1439 
basket study PEMBIB is evaluating pembrolizumab with nintedinib.  1440 
Combination immunotherapy studies with anti-CTLA4 and anti-PD1 immunotherapy has been 1441 
initiated (NBIT01) Finally, Checkmate 743 will evaluate nivolumab/ipilumumab combination in a 1442 
randomised phase III in the front line setting. 1443 
 1444 
 1445 
SECTION 12: RADIOTHERAPY 1446 
 1447 
12.1 Prophylactic radiotherapy to procedure tracts 1448 
 1449 
Subcutaneous tumour nodules, seeded up the tract of previous needle or tube insertions, surgical or 1450 
other invasive procedures, are sometimes observed in MPM patients. Prophylactic radiotherapy to 1451 
these sites may have a role in preventing the development of tumour tract nodules from developing. 1452 
 1453 
Evidence review 1454 
 1455 
Four randomised controlled trials comparing prophylactic radiotherapy to procedure tracts to no 1456 
radiotherapy, and a systematic review (written before the 2016 RCT was published) are evaluated 1457 
[177-181]. The Boutin study  was conducted in the era before chemotherapy was routinely offered 1458 
to MPM patients fit enough to receive it [177]. All patients had had both an Abrams biopsy and a 1459 
thoracoscopy before randomization. The incidence of metastatic nodules in the control group was 1460 
high (40%) and has not been replicated in any other observational studies. The Bydder and O’Rourke 1461 
studies excluded patients who had received prior chemotherapy [178 179]. Information regarding 1462 
subsequent chemotherapy treatment was not available. The incidence of chest wall nodules in the 1463 
control groups were lower and the differences in the incidence of nodules between treatment 1464 
groups not significantly different. It has been questioned whether these studies were adequately 1465 
powered [181]. 1466 
 1467 
The SMART Trial was a randomised, multi-centre, phase III trial evaluating whether prophylactic 1468 
radiotherapy reduces the incidence of procedure tract metastases after surgical and large bore 1469 
pleural procedures [180]. Eligible patients were recruited from 22 UK hospitals and randomised (1:1) 1470 
to immediate radiotherapy (21 Gray in three fractions over three working days), or deferred 1471 
radiotherapy (same dose given if a procedure tract metastasis (PTM) developed). 203 patients were 1472 
randomised (102 to immediate radiotherapy, 101 to deferred radiotherapy). No statistically 1473 
significant difference was identified in the PTM rates of the immediate and deferred radiotherapy 1474 
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groups (9/102 (8·8%) vs 16/101 (15·8%) respectively; OR 0·51 (0·19, 1·32); p=0·14). There was no 1475 
difference identified in quality-of-life, chest pain, analgesia requirements or survival of the two 1476 
groups. 1477 
 1478 
A Phase III Randomised Trial of Prophylactic Irradiation of Tracts in Patients with Malignant Pleural 1479 
Mesothelioma Following Invasive Chest Wall Intervention (the PIT trial) was due to complete 1480 
recruitment in June 2016 and results are expected in 2017 [182]. Table 13 provides a summary of 1481 
trails comparing prophylactic and procedure tracts to no radiotherapy. 1482 
 1483 
Table 13: Summary of trials comparing prophylactic radiotherapy to procedure tracts to no 1484 
radiotherapy 1485 
Study Patients Treatments Nodules in 
treatment 
group 
Nodules in 
control 
group 
Significance Notes 
Boutin 
1995 
[177] 
40 21Gy in 3 
12.5-
15MeV 
0/20 8/20 P<.001 Pre-
Chemotherapy 
Era 
Bydder 
2004 
[178] 
43 
(58 sites) 
10Gy in 1 
9MeV 
2/28 3/30 N.S Chemotherapy 
patients 
excluded   
O’Rouke 
2007 
[179] 
61 21Gy in 3 
250kV 
photons or 
9-12MeV 
4/31 3/30 N.S Chemotherapy 
patients 
excluded  
Clive 
2016 
[180] 
 
203 21Gy in 3 
fractions 
9/102 16/101 N.S Chemotherapy 
included 
 1486 
 1487 
 1488 
Evidence statement 1489 
Three out of four randomised controlled trials did not show a reduction in procedure tract 1490 
metastases with prophylactic radiotherapy to chest wall procedure tracts Level 1+ 1491 
 1492 
Prophylactic radiotherapy to chest wall procedure tract has not been shown to improve quality-of-1493 
life, chest pain, analgesia requirements or survival Level 1+ 1494 
 1495 
Recommendation 1496 
➢ Do not offer prophylactic radiotherapy to chest wall procedure tracts routinely. Grade A 1497 
 1498 
 1499 
 1500 
12.2  Radiotherapy as part of multi-modality treatment 1501 
 1502 
The role of radiotherapy as part of the multimodality treatment of MPM is controversial. 1503 
Radiotherapy can be delivered either as the sole local treatment modality after chemotherapy or as 1504 
an adjuvant/neoadjuvant treatment in the context of a surgical approach. However, as MPM 1505 
typically involves large areas of the pleura, the delivery of radical doses of radiotherapy are limited 1506 
by the surrounding organs at risk such as normal lung, liver, heart and spinal cord. 1507 
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A number of important remarks should be made with regards to the interpretation of the available 1508 
literature. Firstly, the majority of studies identified evaluated multimodality treatment and very few 1509 
investigated specifically the role of pre/postoperative RT or RT alone. Secondly, the majority of the 1510 
studies identified evaluated RT in the context of extra-pleural pneumonectomy which is now very 1511 
rarely performed in the UK. Lastly, none of the studies reviewed included surgical or radiotherapy 1512 
quality assurance. Specifically, the majority of the studies reviewed had no built-in radiation dose 1513 
constraints for organs at risk. 1514 
 1515 
Evidence review 1516 
 1517 
Twenty one studies were identified which included radiotherapy as part of the multimodality 1518 
treatment [154 183-202]. One evaluated pre-operative radiotherapy (in the context of EPP) [183], 1519 
two hemithoracic radiotherapy alone [184 185] and 17 post-operative radiotherapy (4 in the context 1520 
of pleurectomy decortication and 13 in the context of EPP). 1521 
Four studies were retrospective cohort series, and 16 were prospective studies, of which only four 1522 
are multicentre and two are randomised controlled trials (RCT). 1523 
Studies evaluating postoperative radiotherapy either after EPP or PD have shown that RT in the 1524 
context of multimodality treatment is feasible, but some severe toxicities, particularly pneumonitis 1525 
have been reported [154 186-201]. The rate of grade 5 radiation pneumonitis ranges from 0-46% in 1526 
the studies that have reported RT-related toxicity and a lung dose-volume effect was identified in 1527 
patients who developed grade 3+ radiation pneumonitis [186 191 193-195]. 1528 
Only one RCT specifically evaluated the role of post-op radiotherapy and showed no benefit for this 1529 
treatment [201]. The Swiss Group for Clinical Cancer Research (SAKK) trial is a 2-part multicentre 1530 
randomised phase 2 study, analysed on intention to treat. It included patients with pathologically 1531 
confirmed MPM, resectable TNM stages T1–3 N0–2, M0, WHO performance status 0–1 and age <70 1532 
years. In part 1 of the study, patients were given three cycles of neoadjuvant chemotherapy 1533 
followed by EPP; the primary endpoint was complete macroscopic resection (R0–1). In part 2, 1534 
patients with complete macroscopic resection were randomly assigned to receive adjuvant 1535 
radiotherapy or not (3D conformal radiotherapy or intensity-modulated radiotherapy was permitted 1536 
with dose ranging from 55.9 to 57.6 Gy, using a boost technique).The primary endpoint was 1537 
locoregional relapse free survival. 151 patients were evaluable after neoadjuvant chemotherapy, of 1538 
whom 75% had EPP and 64% complete macroscopic resection. 54 patients were enrolled in part 2. 1539 
Median locoregional relapse-free survival from surgery was 7.6 months (95% CI 4.5–10.7) in the no 1540 
radiotherapy group and 9.4 months (6.5–11.9) in the RT group. Median overall survival calculated 1541 
from registration for patients in part 2 was 20·8 months (95% CI 14·4–27·8) in the no RT group and 1542 
19·3 months (11·5–21·8) in the RT group. One patient died of grade 5 radiation pneumonitis. 1543 
However, it should be noted the trial was terminated earlier than planned due to slow accrual (at 1544 
73% of the accrual). 1545 
Evidence statements: 1546 
Post-operative radiotherapy after chemotherapy and extra-pleural pneumonectomy has not been 1547 
shown to improve survival.  Level 1+. 1548 
Post-operative radiotherapy after chemotherapy and pleurectomy decortication has not been shown 1549 
to improve survival.  Level 2-. 1550 
Pre-operative radiotherapy has not been shown to improve survival.  Level 2-. 1551 
Radical radiotherapy used in isolation has not been shown to improve survival.  Level 2-. 1552 
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Recommendation: 1553 
➢ Do not offer pre or post-operative radiotherapy in MPM.  Grade A. 1554 
Research recommendation: 1555 
Prospective clinical trials of preoperative radiotherapy, post-operative radiotherapy after 1556 
pleurectomy decortication and definitive radiotherapy after chemotherapy in MPM are required. 1557 
 1558 
12.3 Radiotherapy for symptom palliation 1559 
 1560 
Symptoms in MPM include pain, breathlessness and cough. Palliative radiotherapy has been used in 1561 
an attempt to control these symptoms, as well as for other indications. 1562 
Evidence review 1563 
There are six studies, of which two explore whole hemi-thorax irradiation [184 203] and four of 1564 
localised treatment to areas of disease and/or symptoms [204-207].  There is one are two systematic 1565 
reviews addressing the role of radiotherapy for symptom palliation which includes these studies 1566 
[208 209].  1567 
Of the hemi-thorax studies: A retrospective case series described no change in chest pain or 1568 
performance status in 47 patients treated with 40Gy in 20 fractions [184]. The other was a 1569 
prospective phase II study without controls, including 19 patients treated with 30Gy in 10 fractions 1570 
[203]. It reported an improvement in pain control in 68% at one month, but this was not maintained 1571 
(1). Toxicity was not reported in this study. 1572 
The localised treatment studies showed variable response rates (in terms of pain improvement). 1573 
The dose and duration of response were also variable in these uncontrolled reports. The results are 1574 
summarised in the Table 14. 1575 
 1576 
 1577 
 1578 
Table 14: Summary of studies exploring localised hemi-thorax irradiation 1579 
Study Type Of Study Patients Dose; number 
of fractions (#) 
Pain 
Improve
ment % 
Duration 
of 
Response 
 
Macleod 
[204] 
 
Prospective 
phase II 
No control 
40 20 Gy ;  5 # 47 5 weeks 
 
Davis [205] 
 
Retrospective 111 <20Gy* 
>40Gy* 
 
60 
57 
No data 
 
Graaf-
Strukowska 
[206] 
Retrospective 189 <4Gy; 1 # 
36Gy; 9# 
40 
50 
98 days 
69 days 
 43 
Post SOCC draft 29/08/2017 
 
 
Jenkins 
[207] 
 
Retrospective 54 36 Gy; 12# 57 2 weeks 
* Fractionation not specified 1580 
 A randomised phase II study opened to recruitment in the UK in August 2016 aiming to establish 1581 
optimal dose/fractionation for symptom control in MPM (SYSTEMS2 SRCTN12698107.) 1582 
Evidence statements: 1583 
Hemi-thorax radiotherapy has not been shown to have a consistent impact on chest pain or 1584 
performance status in MPM.  Level 3. 1585 
Localised radiotherapy can improve pain control in MPM although the effect is variable and is short 1586 
lived.  Level 3. 1587 
Radiation dose fractionation utilised in studies of localized radiotherapy for pain control in MPM are 1588 
variable. The optimal dose is not known.  Level 3. 1589 
Recommendations: 1590 
➢ Do not offer hemi-thorax radiotherapy for MPM. Grade D 1591 
➢ Consider palliative radiotherapy for localised pain in MPM where the pain distribution 1592 
matches areas of underlying disease.  Grade D. 1593 
Research recommendation: 1594 
Further prospective randomised clinical trials are required to determine the role of radiotherapy for 1595 
symptom control in MPM and the optimal dose fractionation. 1596 
 1597 
 1598 
 1599 
SECTION 13: SYMPTOM CONTROL 1600 
 1601 
Review of the literature revealed that there are no randomised controlled studies of symptom 1602 
control in patients with MPM only. 1603 
There is one published case series of 53 patients with pain from MPM managed with cervical 1604 
cordotomy [210]. This was a retrospective case note review and although the majority of patients 1605 
appeared to have a reduction in pain following the procedure this study is subject to considerable 1606 
selection and recall bias.  1607 
Evidence statement 1608 
There are no studies of symptom control that specifically relate to MPM. 1609 
Good practice point 1610 
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✓ Symptoms in MPM should be managed as per current guidelines for cancer in general (see 1611 
Table 15) and early involvement of palliative care specialists is recommended. 1612 
 1613 
Table 15: Summary of current cancer related symptom management guidelines in relation to 1614 
common symptoms seen in MPM 1615 
Symptom Management Reference literature 
Breathlessness Pleural fluid control See Section 9 
 Sustained release morphine Ref [211], [212] 
 Breathing control and use of fans Ref [213-216] 
Pain Opioids Ref [217] [218] 
 Amitryptilline Amitriptyline, duloxetine, 
gabapentin or pregabalin for neuropathic 
pain 
Ref [219] [220] 
 Radiotherapy for refractory localised pain See Section 12 
Fatigue Aerobic exercise Ref [221] 
Anorexia Megestrol Acetate Ref [222] 
 1616 
SECTION 14: CARE AND MANAGEMENT 1617 
 1618 
14.1 Care in multi-disciplinary teams 1619 
 1620 
Multidisciplinary Team (MDT) meetings are an established feature in cancer services.  Widespread 1621 
adoption and development, despite very little supporting evidence, has been seen across all tumour 1622 
types over the last two decades.  There is a suggestion that MDT working improves recruitment to 1623 
clinical trials [223] and that patients find MDT working reassuring and improves their experience of 1624 
care [224 225].  1625 
 1626 
To support the development of MDTs MDT’s the National Cancer Action Team published Guidelines 1627 
on Characteristics of an Effective MDT (NCAT 2010) although given the Mesothelioma incidence the 1628 
option of virtual MDT working should be considered [226].  NHS England have outlined their 1629 
commissioning expectations for Mesothelioma requesting the establishment of specialist 1630 
Mesothelioma MDTs and recommending they manage a minimum of 25 patients per year (NHS 1631 
England 2013).  1632 
 1633 
Bibby et al (2016) recently published a retrospective evaluation of their specialist regional 1634 
mesothelioma MDT based in the south-west of England [227]. Of the 210 cases that were reviewed 1635 
by the specialist MDT, 10% had their diagnoses overturned and 20% were enrolled into a clinical 1636 
trial.  1637 
 1638 
Evidence statement: 1639 
Specialist MPM multidisciplinary meetings may improve diagnostic accuracy and recruitment to 1640 
clinical trials. Evidence Level 3 1641 
 1642 
Recommendation: 1643 
➢ Consider referring MPM cases to a regional mesothelioma MDT.  Grade D 1644 
 1645 
Good Practice Points 1646 
 1647 
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✓ All Mesothelioma cases should be discussed in a timely fashion by a MDT that reviews a 1648 
sufficient number of cases to maintain expertise and competence in the diagnosis and 1649 
treatment of MPM.   1650 
✓ The MDT membership should fulfil the requirements set by national cancer peer review (to 1651 
include a named clinical nurse specialist for MPM).   1652 
✓ The MDT should maintain an up to date portfolio of mesothelioma trials and offer 1653 
recruitment to all eligible patients. 1654 
 1655 
 1656 
14.2 Information needs of patients 1657 
 1658 
Patients undergoing investigation and treatment for mesothelioma may have unmet psychosocial 1659 
and information needs. A clear understanding is essential for patients and their carers to make 1660 
informed choices about the options for management. They may need professional support when 1661 
interpreting information. The NICE guideline on the management of lung cancer (CG121) made 1662 
detailed recommendations on the information and support needs of patients, some of which will be 1663 
applicable to MPM [228] . The National Lung Cancer Forum for Nurses has emphasised the key role 1664 
of the lung clinical nurse specialist in providing information and support to patients and has 1665 
produced specific guidance for managing patients with mesothelioma https://www.nlcfn.org.uk/.  In 1666 
addition, the UK has There are 14 mesothelioma specific clinical nurse specialists in the UK.  1667 
 1668 
Evidence review 1669 
 1670 
The search revealed 13 abstracts potentially relevant to this question. Eight studies were of 1671 
sufficient quality and relevance to be included in the review, of which 4 included less than 30 1672 
patients, therefore the volume of evidence is limited. The studies can be grouped in those assessing 1673 
emotional support, compensation and intervention. 1674 
 1675 
Emotional support 1676 
Granieri et al (2013) collected quality of life data from 27 patients with MPM, 55 relatives and 40 1677 
healthy controls in Italy [229]. Patients with MPM had a greater belief that goals could not be 1678 
reached or problems solved, while often claiming that they were more indecisive than the healthy 1679 
controls. First-degree relatives reported lower opinions of others, a greater belief that goals cannot 1680 
be reached or problems solved, support for the notion that they are indecisive, and were more likely 1681 
to suffer from fear that significantly inhibited normal activities than were healthy controls. Arber 1682 
(2013) interviewed 10 patients with MPM from 2 hospitals in the South of England [230]. All 1683 
participants reported high levels of uncertainty and feelings of a lack of control leading to 1684 
psychosocial distress since receiving their diagnosis. All the participants found it difficult to cope 1685 
with their diagnosis because of all the negative information and ‘bad news’ around MPM, and this 1686 
led to feelings of despair. Clayson et al (2005) interviewed 15 patients in the North of England [231]. 1687 
Four main themes emerged: coping with symptoms, the burden of medical interventions, finding out 1688 
about mesothelioma and psychosocial issues. Dyspnoea was the commonest symptom and the 1689 
unpredictability and often speed of onset caused great distress. All patients acknowledged asbestos 1690 
as the cause of their disease. 1691 
 1692 
A systematic literature review [232] comparing psychological care needs of mesothelioma patients 1693 
and those with advanced lung cancer found there to be similarities between the two populations but 1694 
recommend developing separate assessment and care pathways so that distinct differences 1695 
(hopelessness, legal and financial matters, attribution of blame) can be addressed. 1696 
 1697 
Intervention 1698 
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Moore et al (2008) evaluated a hospital-based mesothelioma support group in London.  Six 1699 
responses were received from twenty one attendees[233] .  All of those that responded found the 1700 
group useful in terms of sharing experiences and gaining information. 1701 
 1702 
Compensation 1703 
Chamming et al. (2013) performed a linked database study in 2407 patients in France and 1704 
determined that 30% of patients with MPM did not claim occupational disease compensation [234]. 1705 
Claims were lower in older patients, women and white collar workers. A similar study by Cree et al 1706 
(2009) of 568 MPM patients in Canada demonstrated that only 42% filed a claim [235]. A 1707 
retrospective case note review (Kuschner et al. 2012) performed in North America identified 16 1708 
patients with mesothelioma treated at 3 Department of Veteran Affairs hospitals of whom only 1 1709 
had documented advice on compensation [236]. 1710 
 1711 
Every serious illness creates extra costs for patients and their families and mesothelioma is no 1712 
exception. Mesothelioma is usually almost always caused by exposure to asbestos. The industrial 1713 
nature of mesothelioma means patients often have complex benefit and compensation claims. This 1714 
information is correct at time of going to press xxxx2017. For all civil claims there is a three year time 1715 
limit from the first date the patient became aware that there is evidence of a compensatable 1716 
asbestos related disease. 1717 
 1718 
There are two main ways to get additional financial support when someone is diagnosed with 1719 
mesothelioma in the UK:   1720 
A] State benefits 1721 
B] Pursuing a civil compensation claim   1722 
 1723 
For all civil claims there is a three year time limit from the first date the patient became aware that 1724 
there is evidence of a compensatable asbestos related disease. 1725 
 1726 
State benefits 1727 
The Department for Work and Pensions recognises the seriousness of mesothelioma and does not 1728 
normally require a medical examination. Patients under the age of 65 are eligible for the Personal 1729 
Independent Payment [PIP], and Attendance Allowance [AA] if the patient is over 65. PIP provides 1730 
financial assistance for patients who need help with daily living including personal care and mobility. 1731 
For patients who have been given a terminal diagnosis they can claim under the Special Rules 1732 
meaning they will be given priority in the claim being dealt with. Under the Special Rules patients 1733 
can receive the allowance at the highest rate. An award of these benefits does not affect an 1734 
individual's right to apply for other means tested benefits. 1735 
Industrial injuries disablement benefit (IIDB) 1736 
This is a non means tested allowance which patients can claim if on the balance of probability they 1737 
were exposed to asbestos at work.  It is not necessary for a person to have worked directly with 1738 
asbestos to get this benefit.  This benefit is paid via direct debit weekly, fortnightly or every 13 1739 
weeks. An award of IIDB will be treated as income and may affect other means tested benefits. 1740 
Pneumoconiosis (Workers Compensation) Act 1979 1741 
This government scheme is designed to compensate those patients exposed to asbestos through 1742 
work. A lump sum payment under the Pneumoconiosis (Workers Compensation) Act 1979 [PWCA] 1743 
can be applied for if on the balance of probability the asbestos exposure occurred during their time 1744 
at work 1745 
  1746 
Diffuse mesothelioma scheme 2008 1747 
If patients are unable to make a claim under the PWCA,  and are not entitled to compensation from 1748 
an MOD [Ministry of Defence] scheme a one off lump sum can be applied for. This is suitable where 1749 
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exposure is from a secondary source, exposure was in the environment, for those who were self-1750 
employed   or where exposure cannot be specified but occurred in the UK. The lump sum is assessed 1751 
by the patient's age. 1752 
A claim can be made for the lump sum by the deceased’s widow or widower, a child under 16, a 1753 
partner who was living with the patient with mesothelioma at the time of death or any other 1754 
relatives who were financially dependent on the patient at the time of death.   The amount paid in 1755 
posthumous claims is lower than in life time benefits. 1756 
 1757 
War disablement pension 1758 
If a patient was exposed during their service in the armed forces prior to 1987 they are not able to 1759 
make a claim from their employer because the crown has immunity. A claim can however be made 1760 
from the Service Personnel and Veterans Agency. All veterans can make a choice between receiving 1761 
a traditional war pension or a lump sum regardless of age at diagnosis. 1762 
 1763 
Civil claim against a previous employer                   1764 
If on the balance of probability exposure to asbestos was from an employer or a previous employer a 1765 
civil claim can be pursued via a specialist solicitor who deals with asbestos claims. Claims are often 1766 
made through the insurers of the company by establishing an employer's negligence or breach of 1767 
statutory duty to protect the worker from the effects of asbestos dust and fibres. If a company or an 1768 
insurer cannot be found, an application to The 2014 Diffuse Mesothelioma Payment scheme can be 1769 
made. 1770 
As part of a civil claim the solicitor may be able to recover costs such as pain and suffering or hospice 1771 
care. All cases are fast tracked with an aim that patients can receive compensation in their lifetime. 1772 
The vast majority of cases are settled without going to court. Careful discussion from a specialist 1773 
solicitor with the patient and family is required because some claims are worth more if the patient is 1774 
not alive has died. 1775 
 1776 
STATE BENEFITS 1777 
The Department for Work and Pensions recognises the seriousness of mesothelioma and does not 1778 
normally require a medical examination. 1779 
 1780 
Patients under the age of 65 are eligible for the Personal Independent Payment [PIP] and 1781 
Attendance Allowance [AA] if the patient is over 65. PIP provides financial assistance for patients 1782 
who need help with daily living including personal care and mobility. For patients who have been 1783 
given a terminal diagnosis they can claim under the Special Rules meaning they will be given priority 1784 
in the claim being dealt with. Under the Special Rules patients can receive the allowance at the 1785 
highest rate. An award of these benefits does not affect an individual’s right to apply for other 1786 
means tested benefits. 1787 
INDUSTRIAL INJURIES DISABLEMENT BENEFIT [IIDB] 1788 
This is a non means tested allowance which patients can claim if on the balance of probability they 1789 
were exposed to asbestos at work or as an apprentice. It isn’t necessary for a person to have worked 1790 
directly with asbestos to get this benefit. This benefit cannot be claimed if you were self-employed in 1791 
the work that led to the asbestos exposure. This benefit is paid via direct debit weekly, fortnightly or 1792 
every 13 weeks. An award of IIDB will be treated as income and may affect other means tested 1793 
benefits. 1794 
 1795 
Pneumoconiosis (Workers Compensation) Act 1979 1796 
This government scheme is designed to compensate those patients exposed to asbestos through 1797 
work but who cannot make a successful civil compensation claim. A lump sum payment under the 1798 
Pneumoconiosis (Workers Compensation) Act 1979 [PWCA] can be applied for if on the balance of 1799 
probability the asbestos exposure occurred during their time at work 1800 
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 1801 
2008 DIFFUSE MESOTHELIOMA SCHEME 1802 
If patients are unable to make a claim under the PWCA, have not received payment in respect of the 1803 
disease from an employer, a civil claim or elsewhere and are not entitled to compensation from an 1804 
MOD [Ministry of Defence]scheme a one off lump sum can  be applied for. This is suitable where 1805 
exposure is from a secondary source, exposure was in the environment, for those who were self-1806 
employed   or where exposure cannot be specified but occurred in the UK. The lump sum is assessed 1807 
by the patient’s age. 1808 
A claim can be made for the lump sum by the deceased’s’ widow or widower, a child under 16, a 1809 
partner who was living with the patient with Mesothelioma at the time of death or any other 1810 
relative who were financially dependent on the patient at the time of death.   The amount paid in 1811 
posthumous claims is lower than in life time benefits. 1812 
 1813 
WAR DISABLEMENT PENSION 1814 
If a patient was exposed during their service in the armed forces prior to 1987 they are not able to 1815 
make a claim from their employer because the crown has immunity. A claim can however be made 1816 
from the Service Personnel and Veterans Agency. All veterans can make a choice between receiving 1817 
a traditional war pension or a lump sum regardless of age at diagnosis. 1818 
 1819 
CIVIL CLAIM AGAINST A PREVIOUS EMPLOYER  1820 
If on the balance of probability exposure to asbestos was from an employer or a previous employer a 1821 
civil claim can be pursued via a specialist solicitor who deals with asbestos claims. Claims are often 1822 
made through the insurers of the company by establishing an employer’s negligence or breach of 1823 
statutory duty to protect the worker from the effects of asbestos dust and fibres. If a company or an 1824 
insurer cannot be found an application to The 2014 Diffuse Mesothelioma Payment scheme can be 1825 
made.  1826 
As part of a civil claim the solicitor may be able to recover costs such as pain and suffering or hospice 1827 
care. All cases are fast tracked with an aim that patients can receive compensation in their lifetime. 1828 
The vast majority of cases are settled without going to court. Careful discussion from a specialist 1829 
solicitor with the patient and family is required because some claims are worth more if the patient is 1830 
not alive. 1831 
 1832 
Intervention 1833 
Moore et al (2008) evaluated a hospital-based mesothelioma support group in London [233]. Six 1834 
responses were received from 21 attendees. All of those that responded found the group useful in 1835 
terms of sharing experiences and gaining information.  1836 
 1837 
Evidence statement 1838 
 1839 
Patients with MPM and their relatives have reduced quality of life compared to healthy controls. 1840 
Level: 2+ 1841 
 1842 
A diagnosis of MPM causes high levels of psychosocial distress. Level: Qualitative 1843 
 1844 
Documentation of compensation advice and subsequent claims are variable. Level: 3 1845 
 1846 
 1847 
Recommendations 1848 
 1849 
➢ Offer accurate and understandable information to patients and carers about compensation 1850 
for MPM. Grade D 1851 
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 1852 
➢ Offer patients with MPM and their carers the opportunity to discuss concerns regarding 1853 
their disease. Grade D 1854 
 1855 
 1856 
 1857 
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15.3 Follow-up strategies 
The literature search did not reveal any evidence pertaining to who and how MPM patients 
should be followed-up. The search identified 12 papers that were thought to be relevant to the 
imaging component of this question. Following review of the 12 abstracts 9 papers [237-245] 
were fully critiqued to answer the question regarding the best form of imaging when following 
up patients with MPM. 
 
None of the papers reviewed were from the UK but a large number were from within the 
European region. The rest from Australia, USA and Turkey. Given the patient populations are 
generally similar this evidence is broadly applicable to the UK population. Most of the studies 
are from the pre-pemetrexed cisplatin chemotherapy era but for the purpose of answering the 
specific question here about follow-up, the results are generally acceptable.    
 
The papers reviewed were consistent in their findings that a bi-dimensional method of 
assessing tumour volume is inadequate in MPM[245]. A number of the studies compared 
Response Evaluation Criteria In Solid Tumors (RECIST) with mRECIST CT criteria. Modified 
RECIST, despite having its limitations, remains the best method of assessing tumour response 
when followed up over a period of time [246 247]. 
 
One study demonstrated using mRECIST criteria in MRI can be better at soft tissue/tumour 
delineation and pleural effusion identification, but when compared with mRECIST criteria in CT 
[248]. 
 
Three studies explored the role of volumetric assessment (using Cavalieri principle) of the 
tumour on CT [246 249 250]. No significant intraclass or interobserver variability noted, but this 
method is a time consuming and onerous way of measuring tumour in MPM therefore limiting 
its clinical utility.    
 
 
Evidence Statements: 
 
CT scanning using modified response evaluation criteria in solid tumours (RECIST) for 
interpretation gives the best assessment of tumour response to chemotherapy.  Level 3. 
 
Recommendation: 
 
➢ In MPM patients where accurate determination of radiological progression is required, 
consider CT with modified RECIST measurement Grade D. 
 
Good practice point 
✓ A personalised care approach should be considered for each patient:  
Patients should be offered 3-4 monthly follow-up appointments with an oncologist, respiratory 
physician or specialist nurse according to their current treatment plan. If patients wish to be 
seen less frequently, offer regular telephone follow-up with specialist nurse with an option to 
attending clinic if in the event of clinical deterioration. 
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Appendix 2:  Prognostic Scores 
 
 
The EORTC Prognostic Score 
 
The score is: 
 
EPS = 0.55 (if WBC>8.3 x 109/L) + 0.6 (if PS=1 or 2) + 0.52 (if histological diagnosis probable or 
possible) + 0.67 (if histology=sarcomatoid) + 0.6 (if male) 
 
The patient has a good prognosis if EPS <= 1.27 and a poor prognosis if EPS > 1.27.   
 
 
 
Information about the CALGB Prognostic groups 
Derivation and validation studies of the CALGB prognostic groups 
Prognostic 
group 
number 
Derivation study, 
Herndon 1998, 
median survival 
(mo), 1yr, 2yr 
Validation study 
Edwards et al 2005, 
median survival 
(mo), 1yr, 2yr 
Validation study, 
Meniawy 2013, 
median survival 
(mo) 
1 13.9, 63%, 38% 
n=36 
14.8, 55.9%, 16.8% 
n=22 16.5 
n=56 2 9.5, 41%, 21% 
n=36 
6.4 
n=2 
3 9.2, 30%, 10% 
n=146 
6.6, 29%, 5.3% 
n=55 14.2 
n=131 4 6.5, 25%, 6% 
n=33 
8.1, 40%, 0% 
n=5 
5 4.4, 7%, 0% 
n=73 
3.4, 3.5%, 0% 
n=30 9.4 
n=80 6 1.4, 0%, 0% 
n=13 
1.1, 0%, 0% 
n=9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 70 
Post SOCC draft 29/08/2017 
The Neutrophil-to-Lymphocyte ratio (NLR): 
Permission to reproduce the Published multivariate analysis of neutrophil to lymphocyte ratio 
in malignant mesothelioma will be sought 
 
 
 
 
Prognostic model using decision tree analysis 
 
 
 
 71 
Post SOCC draft 29/08/2017 
 
 72 
Post SOCC draft 29/08/2017 
The LENT scoring system 1858 
Mnemonic Variable Score 
L Pleural fluid LDH (IU/L)  
<1500 0 
>1500 1 
E ECOG Performance Status  
0 0 
1 1 
2 2 
3-4 3 
N NLR  
<9 0 
>9 1 
T Tumour type  
Low risk (mesothelioma, haematological malignancy) 0 
Moderate risk (breast, renal, gynaecological cancer) 1 
High risk (lung cancer, other tumour types) 2 
 1859 
  1860 
 1861 
 1862 
 1863 
 1864 
 1865 
 1866 
 1867 
 1868 
 1869 
 1870 
 1871 
 1872 
 1873 
 1874 
  1875 
